var title_f20_36_21056="LCDD in liver IF";
var content_f20_36_21056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light chain deposition disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy using anti-kappa light chain antiserum on a liver biopsy from a patient with light chain deposition disease. There is diffuse deposition of kappa light chains. A stain for lambda light chains was negative.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21056=[""].join("\n");
var outline_f20_36_21056=null;
var title_f20_36_21057="Intermediate case 15 answer";
var content_f20_36_21057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Atrioventricular junctional rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing a regular AV junctional rhythm at a rate of about 65 beats/min. The negative (retrograde) P waves following each QRS in lead II are characteristic of a junctional rhythm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21057=[""].join("\n");
var outline_f20_36_21057=null;
var title_f20_36_21058="Urticaria 2";
var content_f20_36_21058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin-colored wheals are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21058=[""].join("\n");
var outline_f20_36_21058=null;
var title_f20_36_21059="Black widow spider (Latrodectus mactans) antivenom: Patient drug information";
var content_f20_36_21059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Black widow spider (Latrodectus mactans) antivenom: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/12/31941?source=see_link\">",
"     see \"Black widow spider (Latrodectus mactans) antivenom: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/23/43381?source=see_link\">",
"     see \"Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat black widow spider bites.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antivenin (",
"       <i>",
"        Lactrodectus mactans",
"       </i>",
"       ) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to horses or horse serum, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11555 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21059=[""].join("\n");
var outline_f20_36_21059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016527\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016526\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016531\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016532\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016534\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016529\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016535\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016536\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/12/31941?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/23/43381?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21060="Normal hair cycle";
var content_f20_36_21060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hair-growth cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal human hair cycle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sinclair, RD, Thai, KE. Chapter 18: Male androgenetic alopecia. In: Endocrinology of the Male Reproductive System, McLachlan, R (Ed). Copyright &copy; 2004 www.endotext.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21060=[""].join("\n");
var outline_f20_36_21060=null;
var title_f20_36_21061="Pathophysiology Ebstein anomaly";
var content_f20_36_21061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of Ebstein's anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21061=[""].join("\n");
var outline_f20_36_21061=null;
var title_f20_36_21062="Aluminum hydroxide: Pediatric drug information";
var content_f20_36_21062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"    see \"Aluminum hydroxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/29/12756?source=see_link\">",
"    see \"Aluminum hydroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ALternaGel&reg; [OTC];",
"     </li>",
"     <li>",
"      Dermagran&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amphojel&reg;;",
"     </li>",
"     <li>",
"      Basaljel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F997109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antacid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protectant, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F997130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"      see \"Aluminum hydroxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antacid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 300-900 mg between meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents and Adults: 600-1200 mg between meals and at bedtime; or 600 mg  5-6 times/day between meals; maximum daily dose: 3600 mg/day; do not use maximum daily dose for more than 2 weeks without physician consultation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Hyperphosphatemia associated with chronic renal failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 30 mg/kg/day in divided doses 3 or 4 times/day; maximum daily dose: 3000 mg/day; titrate to normal serum phosphorus level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents and Adults: 300-600 mg 3 or 4 times/day; maximum daily dose: 3000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Topical: Apply to affected area as needed; reapply at least every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermagran&reg;: 0.275% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 320 mg/5 mL (30 mL [DSC], 360 mL, 473 mL, 480 mL); 600 mg/5 mL (355 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALternaGel&reg;: 600 mg/5 mL (360 mL) [sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F997136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: Shake suspension well before use; dose should be followed with water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antacid:  Administer 1-3 hours after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     To decrease phosphorus: Administer within 20 minutes of a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Topical: For external use only",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F6005844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F997110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Adjunct for the relief of peptic ulcer pain and to promote healing of peptic ulcers; relief of sour stomach or stomach upset associated with hyperacidity; relief of heartburn; treatment of gastritis, esophagitis, and gastroesophageal reflux disease; reduce phosphate absorption in hyperphosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Temporary protection of minor cuts, scrapes, burns, and other skin irritations",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, discoloration of feces (white speckles), fecal impaction, nausea, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia, hypophosphatemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F997114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aluminum salts or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6006477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use oral aluminum hydroxide with caution in patients with decreased bowel motility and dehydration, gastric outlet obstruction, renal failure, CHF, edema, cirrhosis, and in patients who have an upper GI hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F997115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Oral: Hypophosphatemia may occur with prolonged aluminum hydroxide administration or with large doses; aluminum toxicity and osteomalacia may occur in patients with chronic kidney disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Topical: Not for application over deep wounds, puncture wounds, infected areas, or lacerations. When used for self medication (OTC use), consult with healthcare provider if needed for &gt;7 days or for use in children &lt;6 months of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6005843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms insoluble salts with dietary phosphorus decreasing phosphorus absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum-containing antacids are considered low risk during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F997139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for GI complaints, stool frequency; serum phosphate and serum aluminum concentrations in patients with chronic kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6006173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline serum aluminum level &lt;20 mcg/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F997128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neutralizes gastric acidity by reacting with hydrochloric acid in the stomach to form aluminum chloride and water. Topical aluminum hydroxide has astringent and demulcent actions.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F6005845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Dependent on gastric emptying time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fasting state: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One hour after meals: Up to 3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6005846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Excreted by the kidneys (normal renal function): 17% to 30%; combines with dietary phosphate in the intestine and is excreted in the feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F997143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/29/12756?source=see_link\">",
"      see \"Aluminum hydroxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antacids may impair or increase absorption of many drugs; do not take oral medications within 1-2 hours of an antacid dose unless specifically instructed to do so. Report unresolved nausea, malaise, muscle weakness, blood in stool, or abdominal pain.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6006174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of ALternaGel&reg;: &lt;0.11 mEq per 5 mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Avner ED, Harmon W, and Niaudet P, \"Chronic Renal Disease,\"",
"      <i>",
"       Pediatric Nephrology",
"      </i>",
"      , 5th ed, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2003, 1363.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 11. Aluminum Overload and Toxicity in CKD,\" 2002, available at www.kidney.org/professionals/kdoqi/guidelines_bone/guide11.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21062/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13169 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21062=[""].join("\n");
var outline_f20_36_21062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132475\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132476\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997109\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997130\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132462\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132447\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997136\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6005844\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997110\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132497\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997114\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6006477\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997115\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298721\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132456\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6005843\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132469\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997139\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6006173\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997128\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6005845\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6005846\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F997143\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6006174\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13169|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=related_link\">",
"      Aluminum hydroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/29/12756?source=related_link\">",
"      Aluminum hydroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21063="Lymphogranuloma venereum";
var content_f20_36_21063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lymphogranuloma venereum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Jonathan M Zenilman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21063/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/36/21063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphogranuloma venereum (LGV) is a genital ulcer disease caused by the L1, L2, and L3 serovars of Chlamydia trachomatis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/1\">",
"     1",
"    </a>",
"    ]. This infection is found most frequently in tropical and subtropical areas of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis is difficult to establish on clinical grounds alone and frequently relies upon either serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], culture, or more recently, nucleic acid amplification testing (NAAT) of direct specimens.",
"   </p>",
"   <p>",
"    LGV will be reviewed here. Other manifestations of C. trachomatis infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although previously rare, lymphogranuloma venereum (LGV) infection has been increasingly reported in developed countries since 2003. Large outbreaks have been reported in Western Europe and North America, primarily in men who have sex with men (MSM) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/5-10\">",
"     5-10",
"    </a>",
"    ], with the largest outbreak reports from New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/11\">",
"     11",
"    </a>",
"    ] and the United Kingdom (UK) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of these cases have presented as proctitis. A close epidemiologic link between the outbreaks in the Netherlands and New York City was suggested through molecular typing of the serovars.",
"   </p>",
"   <p>",
"    The vast majority of MSM who have acquired LGV are also HIV-infected (76 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"     12",
"    </a>",
"    ]. This is a major public health concern since enhanced shedding of HIV during clinical proctitis could increase the risk of HIV transmission to uninfected men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"     12",
"    </a>",
"    ]. In the UK outbreak of 327 cases of LGV, 4 percent of the patients also had a new diagnosis of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"     12",
"    </a>",
"    ]. Thirty-nine percent had a diagnosis of another sexually transmitted infection and approximately 19 percent were also infected with hepatitis C virus.",
"   </p>",
"   <p>",
"    Prior to the outbreaks in MSM, LGV was primarily endemic in heterosexuals in areas of East and West Africa, India, parts of Southeast Asia, and the Caribbean where it is manifested as the classic form of disease with genital ulcers and lymphadenopathy (without proctitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/2\">",
"     2",
"    </a>",
"    ]. However, LGV is not the predominant cause of genital ulcer disease in a number of these regions despite a high frequency of exposure as evidenced by C. trachomatis antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This was illustrated in a survey of 196 patients with genital ulcers from Madagascar, 79 percent of whom had chlamydial antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/13\">",
"     13",
"    </a>",
"    ]. LGV was confirmed by multiplex polymerase chain reaction (PCR) in only 16 (8 percent). This contrasted with much higher rates of infection with chancroid, syphilis, and HSV of 33, 29 and 10 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of LGV recovery are higher in patients with inguinal buboes or HIV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 113 men who were evaluated in Thailand, LGV was recovered in 12.8 percent and H. ducreyi in 28 percent of clinical specimens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an outbreak of genital ulcer disease in the Bahamas in 1990 to 1992 associated with crack cocaine use, 17 of 47 had either a definite or probable clinical diagnosis of LGV; 43 percent were HIV-infected [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As above, in outbreaks among MSM, HIV serostatus is strongly associated with risk of LGV. In one case control study of 87 MSM who had C. trachomatis serovar L2 compared to 377 MSM who had serovars A through K, HIV seropositivity was the strongest risk factor for LGV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"     8",
"    </a>",
"    ]. In the New York City and UK outbreaks noted above, HIV coinfection was found in 84 and 76 percent, respectively. Classical LGV disease, which is seen in tropical areas, is not highly associated with HIV.",
"   </p>",
"   <p>",
"    Other independent risk factors have included concurrent ulcerative disease, a previously diagnosed sexually transmitted infection, unprotected anal sex, recent travel abroad, and meeting sex partners on the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/9,10,12\">",
"     9,10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphogranuloma venereum (LGV) is predominantly a disease of lymphatic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast to mucosal chlamydial infections in which inflammation is largely limited to the initial site of infection, the LGV serovars induce a lymphoproliferative reaction. This is usually accomplished through direct extension from the primary infection site to the draining lymph nodes. Both LGV serovars and other strains of C. trachomatis appear to bind to epithelial cells via heparan sulfate receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When LGV spreads to produce a lymphangitis, areas of necrosis occur within the nodes, followed by abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ]. In one study of 12 patients, lymph node macrophages contained organisms that stained black with Warthin-Starry stain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/19\">",
"     19",
"    </a>",
"    ]. The organisms clustered within vacuoles and by electron microscopy, both reticulate and elementary bodies were visible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .) Polymerase chain reaction (PCR) testing of the lymph nodes for LGV serovars of C. trachomatis was positive in nine of the 12 cases. The pathologic findings are compatible with LGV or Bartonella (ie, &ldquo;cat scratch&rdquo; disease), but are not diagnostic of either entity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/20\">",
"     20",
"    </a>",
"    ]. One report describes a case of cat scratch disease that appeared to be LGV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/21\">",
"     21",
"    </a>",
"    ]. The lymph node reaction may take several weeks to develop, and can result in substantial inflammation and subsequent fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ]. In a small number of cases, dissemination and systemic disease can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STAGES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three stages of lymphogranuloma venereum (LGV) have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection is characterized by a genital ulcer or a mucosal inflammatory reaction at the site of inoculation. The incubation period is 3 to 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ]. These lesions spontaneously heal within a few days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary stage appears two to six weeks later and is related to local direct extension of the infection to regional lymph nodes (ie, inguinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    femoral nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast to the urogenital infections due to Chlamydia trachomatis (serovars A through K) that are often mild, LGV can cause severe inflammation and invasive infection, often with systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inguinal syndrome occurs in men and is an inflammatory reaction in the superficial and deep inguinal nodes, causing the characteristic \"groove\" sign (",
"      <a class=\"graphic graphic_picture graphicRef61366 \" href=\"UTD.htm?12/29/12755\">",
"       picture 1",
"      </a>",
"      ). These may form buboes (unilateral painful inguinal lymph nodes) and rupture.",
"     </li>",
"     <li>",
"      An anorectal syndrome can also occur, which results in an inflammatory mass present in the rectum and retroperitoneum [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients may present with symptoms of proctocolitis with rectal discharge, anal pain, constipation, fever,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenesmus. There may be hemorrhagic proctocolitis and hyperplasia of intestinal and perirectal lymphatic tissue. This can be mistaken for inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/6,7,22\">",
"       6,7,22",
"      </a>",
"      ]. Complications include chronic colorectal fistulas and strictures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Late lymphogranuloma venereum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosis and strictures in the anogenital tract characterize late LGV, which can arise if earlier stages of infection are untreated or undertreated. Late complications include genital elephantiasis, anal fistulae and strictures, frozen pelvis, and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lymphogranuloma venereum (LGV) is difficult because there is no characteristic clinical presentation and laboratory procedures for this pathogen are not well standardized and serologic assessment has low specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17,20,25\">",
"     17,20,25",
"    </a>",
"    ]. However, nucleic acid amplification testing is available in many commercial and public health laboratories. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Nucleic acid amplification testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with genital disease, genital and lymph node specimens (eg, lesion swab or bubo aspirate) may be tested for C. trachomatis by culture, direct immunofluorescence, or nucleic acid detection. Nucleic acid amplification techniques are not approved by the US Food and Drug Administration (FDA) for testing rectal specimens, although this is an area where practice is rapidly evolving, and studies have demonstrated high sensitivity and specificity for Chlamydia diagnosis at this site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/26\">",
"     26",
"    </a>",
"    ]. However, differentiating the LGV from non-LGV serotypes of Chlamydia is challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/27\">",
"     27",
"    </a>",
"    ]. Although polymerase chain reaction-based methods have been developed for this purpose, they are not widely or commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/25,28\">",
"     25,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnosis of LGV proctitis might be suspected in men who have sex with men (MSM) who present with proctitis, enlarged inguinal lymph nodes, and the presence of anorectal ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"     8",
"    </a>",
"    ]. These patients may present to a variety of providers, including primary care physicians, gastroenterologists, and surgeons. Taking an accurate sexual history, and thinking of the possibility of LGV, is key to making the diagnosis.",
"   </p>",
"   <p>",
"    Rectal inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding is almost always present in symptomatic proctitis due to LGV. In the large United Kingdom outbreak, the major symptoms included rectal discharge (79 percent), pain (69 percent), rectal bleeding (58 percent), tenesmus (29 percent), constipation (25 percent); four percent of patients had concomitant urogenital LGV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients where the diagnosis is uncertain, a reasonable approach may be to obtain anoscopy with subsequent microscopic examination of visible areas of proctitis or ulcerative lesions, as noted in the following diagnostic algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef50993 \" href=\"UTD.htm?21/0/21519\">",
"     algorithm 1",
"    </a>",
"    ). In one study, of 87 MSM with proven LGV, microscopic examination of Gram-stained anorectal smear specimens revealed greater than 10",
"    <span class=\"nowrap\">",
"     WBC/hpf",
"    </span>",
"    for the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"     8",
"    </a>",
"    ]. This finding is not diagnostic, but may suggest the need for further studies. However, most patients have only microscopic disease with inflammation in the lamina propria and neutrophilic infiltration of crypts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a multitude of problems associated with attempts to culture the organism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the primary lesion is often missed, culture at this stage of infection is not frequently performed.",
"     </li>",
"     <li>",
"      The yield is low from ulcers or lymph node aspirates; organisms are recovered only 30 percent of the time in the secondary phase of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia cultures are not generally available outside of referral centers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the UK, culture has been widely used to diagnose non-LGV and LGV-chlamydia from rectal specimens. Current guidelines in the UK recommend typing of all chlamydial rectal isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests, complement fixation (CF) or microimmunofluorescence (MIF), are the most common means to diagnose LGV, but all have limitations since they do not distinguish the serotypes and are insensitive for diagnosis of isolated proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/13\">",
"     13",
"    </a>",
"    ]. A positive serologic test for IgG antibodies, in the presence of a compatible clinical syndrome, is considered supportive of a presumptive diagnosis of LGV. Most authorities recommend that a titer of &gt;1:64 rules in the diagnosis, while a titer of &lt;1:32 rules it out [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. Serial titers demonstrating a titer rise are confirmatory. MIF is more sensitive and specific than CF, but neither test can distinguish recent from past infection. Thus, the results of serologic testing must be correlated with the clinical manifestations.",
"   </p>",
"   <p>",
"    Aspirates from buboes can be evaluated by immunofluorescence for the presence of inclusion bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"     17",
"    </a>",
"    ] but are still relatively insensitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nucleic acid amplification testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification techniques (NAAT) of rectal specimens is not currently approved by the FDA. However, there is a growing body of research in this area that suggest high sensitivity and specificity using NAAT of greater than 95 percent compared to culture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers at the Centers for Disease Control and Prevention (CDC) announced in the summer of 2006 that they had developed a new polymerase chain reaction test for the detection of chlamydial DNA specific for LGV as part of an epidemiologic investigation of LGV proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. The assay correctly identified 53 of 55 LGV specimens, 34 of 34 non-LGV chlamydial specimens, and 30 of 30 specimens with no chlamydial infection. The test turnaround time is rapid and testing can be performed on rectal and pharyngeal swab specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Further work on commercially available Chlamydia assays demonstrated that NAAT tests have high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on which resources are available, clinicians should send rectal swabs to either their local or state laboratory initially. If rectal LGV is suspected (eg, in a high-risk MSM), public health authorities would be notified to assure appropriate management of the specimen. Decisions on whether the specimen should go to the CDC for additional testing are made in conjunction with local public health officials. At CDC, specimens will be tested for C. trachomatis, and if positive, will be genotyped for the identification of LGV. For additional information, please contact the CDC at cdclgvinfo@cdc.gov.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Frei skin test, which utilized material derived from chlamydial antigens, is of enormous historical interest, but had low sensitivity and specificity and is no longer produced commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medical therapy for lymphogranuloma venereum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of antibiotics both cures the infection and helps prevent further damage to tissues, although scarring can ensue in areas of tissue reaction, particularly if diagnosis and treatment are delayed.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC), the United Kingdom guidelines for the treatment of sexually transmitted diseases, the European Guidelines, and the Medical Letter recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily for 21 days) as the preferred treatment for lymphogranuloma venereum (LGV), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    500 mg four times daily as a second-line choice (",
"    <a class=\"graphic graphic_table graphicRef76844 \" href=\"UTD.htm?34/48/35596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/12,33-36\">",
"     12,33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC guidelines note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 g orally once weekly for three weeks), which is highly active against C. trachomatis causing cervicitis and urethritis, may be effective in LGV as well.",
"   </p>",
"   <p>",
"    Patients with HIV infection should receive the same regimen as those who are seronegative with close follow-up to assure resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Aspiration of buboes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buboes may require needle aspiration or incision and drainage to avoid rupture or sinus tract formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Empiric therapy for proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a clinical syndrome consistent with LGV proctocolitis should be given empiric therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily for seven days) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg given once intramuscularly) pending the results of laboratory tests.",
"   </p>",
"   <p>",
"    If anorectal chlamydia is confirmed, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    should be continued for at least seven days, which is ample for non-LGV chlamydia. LGV serovar typing for all men who have sex with men with confirmed anorectal chlamydia should then be performed. If the diagnosis of LGV is established, treatment should continue for 21 days or for as long as symptoms persist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3549928\">",
"    <span class=\"h2\">",
"     Treatment during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant and lactating mothers should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg orally four times a day for 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21063/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    may also be effective, but there are no published data to support the efficacy of this agent for LGV during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SEX PARTNERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who have had sexual contact with a patient who has lymphogranuloma venereum within 60 days before onset of the patient's symptoms should be examined, tested for urethral or cervical chlamydial infection, and treated with a standard chlamydia regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    1 gram orally for a single dose or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg orally twice a day for seven days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HIV AND OTHER SEXUALLY TRANSMITTED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients diagnosed with lymphogranuloma venereum should be tested for HIV infection and other sexually transmitted diseases. Men who have sex with men with LGV should also be tested for hepatitis B and C, because of high coinfection rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14363462\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphogranuloma venereum (LGV), a genital ulcer disease caused by the L1, L2, and L3 serovars of Chlamydia trachomatis, is found most frequently in tropical and subtropical areas of the world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LGV is primarily endemic in heterosexuals in areas of East and West Africa, India, parts of Southeast Asia, and the Caribbean. However, LGV has also been reported as a cause of proctitis in men who have sex with men (MSM) within large outbreaks in Western Europe and North America. Risk factors for LGV proctitis have included HIV infection (among MSM), concurrent ulcerative disease, prior history of sexually transmitted infections, unprotected anal sex, recent travel abroad, and meeting sex partners on the internet. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to mucosal chlamydial infections, in which inflammation is largely limited to the initial site of infection, the LGV serovars induce a lymphoproliferative reaction. This is usually accomplished through direct extension from the primary infection site to the draining lymph nodes. &nbsp;(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary infection is characterized by a genital ulcer at the site of inoculation. The secondary stage appears two to six weeks later and is related to local direct extension of the infection to regional lymph nodes (ie, inguinal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      femoral nodes). An anorectal syndrome can also occur, which results in an inflammatory mass in the rectum and retroperitoneum. Patients with proctocolitis may present with rectal discharge, anal pain, constipation, fever, and or tenesmus. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Stages of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If LGV is not recognized and treated, fibrosis and strictures can form in the anogenital tract leading to genital elephantiasis, anal fistulae and strictures, frozen pelvis, and infertility. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Late lymphogranuloma venereum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of LGV is difficult because there is no characteristic clinical presentation, cultures have low yield, and serologic assessment has low specificity. However, more commercial laboratories are performing nucleic acid amplification testing for LGV, which is highly sensitive and specific. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of antibiotics cures infection and prevents further tissue damage in patients with ulcerative disease. United States and European guidelines state that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily for 21 days) is the preferred treatment for LGV.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      (1 g orally once weekly for three weeks), which is highly active against serovars of C. trachomatis that cause cervicitis and urethritis, may be effective in LGV as well. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Buboes may require needle aspiration or incision and drainage to avoid rupture or sinus tract formation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Aspiration of buboes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute proctocolitis should be evaluated for Chlamydia, Neisseria gonorrhea, and syphilis. Empiric therapy including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily for seven days) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (250 mg given once intramuscularly) should be administered while awaiting results of laboratory testing. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients diagnosed with LGV should be tested for HIV infection and other sexually transmitted diseases. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'HIV and other sexually transmitted diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/2\">",
"      Scieux C, Barnes R, Bianchi A, et al. Lymphogranuloma venereum: 27 cases in Paris. J Infect Dis 1989; 160:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/3\">",
"      Behets FM, Brathwaite AR, Hylton-Kong T, et al. Genital ulcers: etiology, clinical diagnosis, and associated human immunodeficiency virus infection in Kingston, Jamaica. Clin Infect Dis 1999; 28:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/4\">",
"      Ndinya-Achola JO, Kihara AN, Fisher LD, et al. Presumptive specific clinical diagnosis of genital ulcer disease (GUD) in a primary health care setting in Nairobi. Int J STD AIDS 1996; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/5\">",
"      Rosen T, Brown TJ. Cutaneous manifestations of sexually transmitted diseases. Med Clin North Am 1998; 82:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/6\">",
"      Blank S, Schillinger JA, Harbatkin D. Lymphogranuloma venereum in the industrialised world. Lancet 2005; 365:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/7\">",
"      Nieuwenhuis RF, Ossewaarde JM, G&ouml;tz HM, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004; 39:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/8\">",
"      Van der Bij AK, Spaargaren J, Morr&eacute; SA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin Infect Dis 2006; 42:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/9\">",
"      Meyer T, Arndt R, von Krosigk A, Plettenberg A. Repeated detection of lymphogranuloma venereum caused by Chlamydia trachomatis L2 in homosexual men in Hamburg. Sex Transm Infect 2005; 81:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/10\">",
"      Herida M, Sednaoui P, Couturier E, et al. Rectal lymphogranuloma venereum, France. Emerg Infect Dis 2005; 11:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/11\">",
"      Pathela P, Blank S, Schillinger JA. Lymphogranuloma venereum: old pathogen, new story. Curr Infect Dis Rep 2007; 9:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/12\">",
"      Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United kingdom. Clin Infect Dis 2007; 44:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/13\">",
"      Behets FM, Andriamiadana J, Randrianasolo D, et al. Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. J Infect Dis 1999; 180:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/14\">",
"      Brathwaite AR, Figueroa JP, Ward E. A comparison of prevalence rates of genital ulcers among persons attending a sexually transmitted disease clinic in Jamaica. West Indian Med J 1997; 46:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/15\">",
"      Viravan C, Dance DA, Ariyarit C, et al. A prospective clinical and bacteriologic study of inguinal buboes in Thai men. Clin Infect Dis 1996; 22:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/16\">",
"      Bauwens JE, Orlander H, Gomez MP, et al. Epidemic Lymphogranuloma venereum during epidemics of crack cocaine use and HIV infection in the Bahamas. Sex Transm Dis 2002; 29:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/17\">",
"      Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect 2002; 78:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/18\">",
"      Chen JC, Stephens RS. Trachoma and LGV biovars of Chlamydia trachomatis share the same glycosaminoglycan-dependent mechanism for infection of eukaryotic cells. Mol Microbiol 1994; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/19\">",
"      Hadfield TL, Lamy Y, Wear DJ. Demonstration of Chlamydia trachomatis in inguinal lymphadenitis of lymphogranuloma venereum: a light microscopy, electron microscopy and polymerase chain reaction study. Mod Pathol 1995; 8:924.",
"     </a>",
"    </li>",
"    <li>",
"     Jones RB, Batteiger BE. Chlamydia trachomatis (trachoma, perinatal infections, lymphogranuloma venereum, and other genital infections). In: Principles and Practice of Infectious Diseases, Fifth Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/21\">",
"      Hagley M, Carne CA, Gorgees N. A case of cat scratch disease masquerading as lymphogranuloma venereum. Int J STD AIDS 1999; 10:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/22\">",
"      Bauwens JE, Lampe MF, Suchland RJ, et al. Infection with Chlamydia trachomatis lymphogranuloma venereum serovar L1 in homosexual men with proctitis: molecular analysis of an unusual case cluster. Clin Infect Dis 1995; 20:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/23\">",
"      Lynch CM, Felder TL, Schwandt RA, Shashy RG. Lymphogranuloma venereum presenting as a rectovaginal fistula. Infect Dis Obstet Gynecol 1999; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/24\">",
"      Papagrigoriadis S, Rennie JA. Lymphogranuloma venereum as a cause of rectal strictures. Postgrad Med J 1998; 74:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/25\">",
"      Chen CY, Chi KH, Alexander S, et al. The molecular diagnosis of lymphogranuloma venereum: evaluation of a real-time multiplex polymerase chain reaction test using rectal and urethral specimens. Sex Transm Dis 2007; 34:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/26\">",
"      Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010; 48:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/27\">",
"      van der Snoek EM, Ossewaarde JM, van der Meijden WI, et al. The use of serological titres of IgA and IgG in (early) discrimination between rectal infection with non-lymphogranuloma venereum and lymphogranuloma venereum serovars of Chlamydia trachomatis. Sex Transm Infect 2007; 83:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/28\">",
"      Chen CY, Chi KH, Alexander S, et al. A real-time quadriplex PCR assay for the diagnosis of rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia trachomatis infections. Sex Transm Infect 2008; 84:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/29\">",
"      McLean CA, Stoner BP, Workowski KA. Treatment of lymphogranuloma venereum. Clin Infect Dis 2007; 44 Suppl 3:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/30\">",
"      Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/31\">",
"      Hampton T. Lymphogranuloma venereum targeted: those at risk identified; diagnostic test developed. JAMA 2006; 295:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/32\">",
"      Lister NA, Tabrizi SN, Fairley CK, Garland S. Validation of roche COBAS Amplicor assay for detection of Chlamydia trachomatis in rectal and pharyngeal specimens by an omp1 PCR assay. J Clin Microbiol 2004; 42:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/33\">",
"      National guideline for the management of lymphogranuloma venereum. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/34\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/35\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21063/abstract/36\">",
"      de Vries HJ, Morr&eacute; SA, White JA, Moi H. European guideline for the management of lymphogranuloma venereum, 2010. Int J STD AIDS 2010; 21:533.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7593 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21063=[""].join("\n");
var outline_f20_36_21063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14363462\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STAGES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Late lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nucleic acid amplification testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medical therapy for lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Aspiration of buboes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Empiric therapy for proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3549928\">",
"      Treatment during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF SEX PARTNERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV AND OTHER SEXUALLY TRANSMITTED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14363462\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7593|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/0/21519\" title=\"algorithm 1\">",
"      Lab confirm of LGV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7593|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/29/12755\" title=\"picture 1\">",
"      Inguinal syndrome in LGV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/48/35596\" title=\"table 1\">",
"      Rx Chlamydia trachomatis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21064="Budesonide (systemic therapy and oral inhalation): Pediatric drug information";
var content_f20_36_21064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10873?source=see_link\">",
"    see \"Budesonide (systemic therapy and oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=see_link\">",
"    see \"Budesonide (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7998594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Entocort&reg; EC;",
"     </li>",
"     <li>",
"      Pulmicort Flexhaler&reg;;",
"     </li>",
"     <li>",
"      Pulmicort Respules&reg;;",
"     </li>",
"     <li>",
"      Uceris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7998595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Entocort&reg;;",
"     </li>",
"     <li>",
"      Pulmicort&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10586184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10586284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10873?source=see_link\">",
"      see \"Budesonide (systemic therapy and oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nebulization:",
"     </b>",
"     Pulmicort&reg; Respules&reg;: Doses should be titrated to the lowest effective dose once asthma is controlled: Manufacturer's recommendations: Children 12 months to 8 years (",
"     <b>",
"      Note:",
"     </b>",
"     Use may be considered in older children or adolescents unable to effectively use metered-dose inhalers):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Previously treated with bronchodilators alone: Initial: 0.25 mg twice daily or 0.5 mg once daily; maximum dose: 0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Previously treated with inhaled corticosteroids: Initial: 0.25 mg twice daily or 0.5 mg once daily; maximum dose: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Previously treated with oral corticosteroids: Initial: 0.5 mg twice daily or 1 mg once daily; maximum dose: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symptomatic children not responding to nonsteroidal asthma medications: Initial: 0.25 mg once daily may be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;6 years: Limited data available; optimal dose and duration of treatment not established; several dosage regimens have been evaluated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Active Crohn&rsquo;s disease (treatment): 9 mg/day given once daily for 7-8 weeks (Escher, 2004; Levine, 2003; Levine, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance of remission: 6 mg/day given once daily for 3-4 weeks (Escher, 2004; Levine, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     One study in children 10-19 years of age showed a trend for higher remission rates using an induction dose of 12 mg/day given once daily for 4 weeks, followed by 9 mg/day for 3 weeks, followed by 6 mg/day for 3 weeks (Levine, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Active Crohn's disease (treatment): 9 mg once daily in the morning for &le;8 weeks; may repeat the 8-week course for recurring episodes of active Crohn's disease;",
"     <b>",
"      Note:",
"     </b>",
"     When switching patients from oral prednisolone to oral budesonide, do not stop prednisolone abruptly; prednisolone taper should begin at the same time that budesonide is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance of remission: Following treatment of active disease and control of symptoms (Crohn's Disease Activity Index &lt;150), use 6 mg once daily for up to 3 months; if symptoms are still controlled at 3 months, taper the dose to complete cessation; continuing remission dose &gt;3 months has not been demonstrated to result in substantial benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Oral inhalation:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be titrated to the lowest effective dose once asthma is controlled; Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;6 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pulmicort&reg; Turbuhaler&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously treated with bronchodilators alone or with inhaled corticosteroids: Initial: 200 mcg (1 puff) twice daily; maximum dose: 400 mcg (2 puffs) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treated with oral corticosteroids: Initial: 400 mcg (2 puffs) twice daily (maximum dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pulmicort&reg; Flexhaler&reg;: Initial: 180 mcg twice daily (some patients may be initiated at 360 mcg twice daily); maximum: 360 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pulmicort&reg; Turbuhaler&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Previously treated with bronchodilators alone: Initial: 200-400 mcg (1-2 puffs) twice daily; maximum dose: 400 mcg (2 puffs) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treated with inhaled corticosteroids: Initial: 200-400 mcg (1-2 puffs) twice daily; maximum dose: 800 mcg (4 puffs) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treated with oral corticosteroids: Initial: 400-800 mcg (2-4 puffs) twice daily; maximum dose: 800 mcg (4 puffs) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pulmicort&reg; Flexhaler&reg;: Initial: 360 mcg twice daily (selected patients may be initiated at 180 mcg twice daily); maximum: 720 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      NIH Asthma Guidelines",
"     </b>",
"     (NAEPP, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nebulization [give once daily or in divided doses twice daily]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children &le;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Low\" dose: 0.25-0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Medium\" dose: &gt;0.5-1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"High\" dose: &gt;1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Low\" dose: 0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Medium\" dose: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"High\" dose: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral inhalation [give in divided doses twice daily]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Low\" dose: 180-400 mcg/day (90 mcg/inhalation: 2-4 inhalations/day or 180 mcg/inhalation: 1-2 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Medium\" dose: &gt;400-800 mcg/day (90 mcg/inhalation: 4-8 inhalations/day or 180 mcg/inhalation: 2-4 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"High\" dose: &gt;800 mcg/day (90 mcg/inhalation: &gt;8 inhalations/day or 180 mcg/inhalation: &gt;4 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Low\" dose: 180-600 mcg/day (90 mcg/inhalation: 2-6 inhalations/day or 180 mcg/inhalation: 1-3 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"Medium\" dose: &gt;600-1200 mcg/day (90 mcg/inhalation: 6-13 inhalations/day or 180 mcg/inhalation: 3-6 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     \"High\" dose: &gt;1200 mcg/day (90 mcg/inhalation: &gt;13 inhalations/day or 180 mcg/inhalation: &gt;6 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in moderate to severe liver dysfunction:",
"     </b>",
"     Oral: Monitor for signs and symptoms of hypercorticism; consider dosage reduction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7998744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, enteric coated, oral: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entocort&reg; EC: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Flexhaler&reg;: 90 mcg/inhalation (165 mg) [contains lactose; delivers ~80 mcg/inhalation; 60 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Flexhaler&reg;: 180 mcg/inhalation (225 mg) [contains lactose; delivers ~160 mcg/inhalation; 120 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, for nebulization: 0.25 mg/2 mL (30s); 0.5 mg/2 mL (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Respules&reg;: 0.25 mg/2 mL (30s); 0.5 mg/2 mL (30s); 1 mg/2 mL (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uceris&trade;: 9 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7998596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule; suspension for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10586344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Shake gently with a circular motion before use. Administer only with a compressed air driven jet nebulizer; do not use an ultrasonic nebulizer; use adequate flow rates and administer via appropriate size face mask or mouthpiece. Avoid exposure of nebulized medication to eyes. Rinse mouth following treatments to decrease risk of oral candidiasis (wash face if using face mask).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to meals; do not chew, crush, break, or open capsule; swallow whole; do not administer with grapefruit juice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhaler:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pulmicort Flexhaler&reg;: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake prior to use. Unit should be primed prior to first use. Place mouthpiece between lips and inhale forcefully and deeply. Do not exhale through inhaler; do not use a spacer. Discard when dose indicator reads \"0\". Rinse mouth with water after use to reduce incidence of candidiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pulmicort Turbuhaler&reg;: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake inhaler after dose is loaded. Unit should be primed prior to first use. Place mouthpiece between lips and inhale forcefully and deeply; mouthpiece should face up. Do not exhale through inhaler; do not use a spacer. When a red mark appears in the dose indictor window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded. Rinse mouth with water after use to reduce incidence of candidiasis.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10586244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Store in a tightly closed container at 25&deg;C (77&deg;F) with excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Store Respules&reg; upright at room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; do not refrigerate or freeze; do not mix with other medications; after foil packet has been opened, Respules&reg; are stable for 2 weeks when protected from light; return unused Respules&reg; to foil packet to protect from light; use opened Respules&reg; promptly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhaler: Keep clean and dry; store at room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10586185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Maintenance therapy and prophylaxis of bronchial asthma (FDA approved in ages 1-8 years);",
"     <b>",
"      not",
"     </b>",
"     indicated for the relief of acute bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation: Long-term (chronic) control of persistent bronchial asthma (FDA approved in ages &ge;6 years and adults);",
"     <b>",
"      not",
"     </b>",
"     indicated for the relief of acute bronchospasm; also indicated in bronchial asthma patients requiring oral corticosteroids (inhalation may decrease or eliminate need for oral steroids over time) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon (FDA approved in adults); maintenance of remission (for up to 3 months) of mild to moderate Crohn's disease of the ileum and/or ascending colon (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7998654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral capsules:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, facial edema, flushing, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, amnesia, confusion, dizziness, fever, headache, insomnia, malaise, nervousness, sleep disorder, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, bruising, dermatitis, eczema, hirsutism, purpura, skin disorder, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal insufficiency, hypokalemia, intermenstrual bleeding, menstrual disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Anus disorder, appetite increased, Crohn's disease exacerbation, diarrhea, dyspepsia, enteritis, epigastric pain, gastrointestinal fistula, glossitis, hemorrhoids, intestinal obstruction, nausea, oral candidiasis, tongue edema, tooth disorder, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Dysuria, hematuria, micturition frequency, nocturia, pyuria, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, leukocytosis, neutrophils abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, hyperkinesia, muscle cramping, myalgia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Eye abnormality, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Bronchitis, dyspnea, pharynx disorder, respiratory infection, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Abscess, C-reactive protein increased, diaphoresis, fat redistribution (moon face, buffalo hump), flu-like syndrome, erythrocyte sedimentation rate increased, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, intracranial hypertension (benign), mood swings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral inhaler (Pulmicort Flexhaler&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, gastroenteritis (viral), nausea, oral candidiasis, taste perversion, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, fracture, hypertonia, myalgia, neck pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, cough, nasal congestion, nasopharyngitis, pharyngitis, respiratory infection, rhinitis, sinusitis, upper respiratory tract infection (viral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressiveness, anxiety, cataracts, depression, glaucoma, hypercorticism, hypersensitivity reactions (immediate and delayed [includes rash, contact dermatitis, angioedema, bronchospasm, urticaria]), hypocorticism, intraocular pressure increased, irritability, nervousness, psychosis, restlessness, throat irritation, wheezing (patients with severe milk allergy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral tablets:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, mood swings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acne, hirsutism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cortisol decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, constipation, flatulence, nausea, upper abdominal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, intracranial hypertension (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Suspension for nebulization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dysphonia, fatigue, mood swings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, eczema, pruritus, purpura, pustular rash, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, gastroenteritis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Cervical lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fracture, hyperkinesia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis, eye infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Earache, ear infection, otitis externa, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, epistaxis, respiratory infection, rhinitis, stridor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, flu-like syndrome, herpes simplex, infection, moniliasis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressiveness, anxiety, avascular necrosis of the femoral head, bronchitis, bruising, cataracts, depression, facial skin irritation, fever, glaucoma, growth suppression, headache, hypercorticism, hypersensitivity reactions (immediate and delayed [includes angioedema, bronchospasm, urticaria]), hypocorticism, intraocular pressure increased, irritability, nervousness, osteoporosis, pain, pharyngitis, psychosis, restlessness, sinusitis, throat irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10586224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to budesonide or any component; Oral inhalation and nebulization: Primary treatment of status asthmaticus or other acute episodes of bronchial asthma when intensive treatment is needed",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10586226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via oral, inhaled, or nebulized (monitor growth). Use of oral, inhaled, or nebulized budesonide in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Use oral budesonide with caution in patients with hypertension, tuberculosis, osteoporosis, diabetes mellitus, peptic ulcer disease, glaucoma, cataracts, or a family history of glaucoma or diabetes mellitus; use oral budesonide with caution and consider dosage reduction in patients with hepatic cirrhosis. Use inhaled budesonide with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Rare cases of increased IOP, glaucoma, or cataracts may occur with inhaled corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10586225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to aerosol or oral steroids with poor bioavailability; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day may be at greater risk; during this period of HPA suppression, aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic glucocorticoid or mineral corticoid activity needed to treat patients requiring stress doses (ie, patients with major stress, such as trauma, surgery, infections, or other conditions associated with severe electrolyte loss). When used at high doses, HPA suppression may occur; use with inhaled or systemic corticosteroids (even alternate-day dosing) or when switching patients from systemic corticosteroids to oral budesonide (due to lower bioavailability) may increase risk of HPA suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Bronchospasm may occur after use of inhaled asthma medications. Powder for oral inhalation (Pulmicort&reg; Flexhaler&reg;) contains lactose (milk proteins) which may cause allergic reactions in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7998671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7998672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Concurrent use of telaprevir with budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7998645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (capsule, tablet)/B (inhalation) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7998646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies of pregnant women have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Studies of pregnant women using inhaled budesonide have not demonstrated an increased risk of abnormalities. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; budesonide is preferred (ACOG, 2008; NAEPP, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10586345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients; inhalation: Check mucous membranes for signs of fungal infection; Asthma: FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; Long-term use: Regular eye examinations and IOP",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10586245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10586246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects are due to direct local effect, rather than systemic absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization (control of asthma symptoms): Within 2-8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral inhalation: Within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization: 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral inhalation: &ge;1-2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10586247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 4-6 years: 3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: ~200 L or 2.2-3.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively metabolized by the liver via cytochrome P450 CYP3A isoenzyme to 2 major metabolites: 16&alpha;-hydroxyprednisolone and 6&beta;-hydroxybudesonide; both are &lt;1% as active as parent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization: Children 4-6 years: 6%;",
"     <b>",
"      Note:",
"     </b>",
"     AUC of single 1 mg dose was comparable to a single 2 mg dose in healthy adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 9% in healthy volunteers and 21% in patients with Crohn&rsquo;s disease (large first pass effect);",
"     <b>",
"      Note:",
"     </b>",
"     Oral bioavailability is 2.5-fold higher in patients with hepatic cirrhosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral inhalation: 39% of an inhaled metered dose is available systemically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 4-6 years: 2.3 hours (after nebulization)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 10-14 years: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nebulization: 10-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral inhalation (Pulmicort Flexhaler&reg;): 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 60% to 66% of dose renally excreted as metabolites; no unchanged drug found in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 4-6 years: 0.5 L/minute (~50% greater than healthy adults after weight adjustment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.9-1.8 L/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10586346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=see_link\">",
"      see \"Budesonide (systemic therapy and oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay. May cause dry mouth. Report acute nervousness or inability to sleep; severe sneezing or nosebleed; difficulty breathing, sore throat, hoarseness, or bronchitis; respiratory difficulty or bronchospasms; disturbed menstrual pattern; vision changes; or loss of taste or smell perception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: This is not a bronchodilator and will not relieve acute asthma attacks; it may take several days for full effects of treatment to occur. Rinse mouth after treatment and wash face after using face mask to decrease chance of oral candidiasis and steroid effects on skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Avoid grapefruit juice and grapefruit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhaler: This is not a bronchodilator and will not relieve acute asthma attacks; it may take several days for full effects of treatment to occur. Rinse mouth after inhalation to decrease chance of oral candidiasis; report sore mouth or mouth lesions to physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10586347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If bronchospasm with wheezing occurs after use of oral inhaler, a fast-acting bronchodilator may be used; discontinue orally inhaled corticosteroid and initiate alternative chronic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide nebulization: A 12-week study in infants (n=141; 6-12 months of age) receiving budesonide nebulizations (0.5 mg or 1 mg once daily) vs placebo demonstrated a budesonide dose-dependent suppression of linear growth; in addition, although mean changes from baseline did not indicate budesonide-induced adrenal suppression, 6 infants who received budesonide had subnormal stimulated cortisol levels at week 12. Children and adolescents (n=18; 6-15 years) receiving budesonide nebulizations of 1 and 2 mg twice daily showed a significant reduction in urinary cortisol excretion; this reduction was not seen when patients were dosed at 1 mg/day (maximum recommended dose). Long-term effects of chronic use of budesonide nebulization on immunological or developmental processes of upper airways, mouth, and lung are unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral budesonide: A retrospective study of 62 children (mean age: 14.1 &plusmn; 2.5 years; range: 9.5-18 years) used oral budesonide in doses of 0.45 mg/kg/day (maximum dose: 9 mg/day) for the treatment of mild to moderate Crohn's disease (Levine, 2002). In a prospective, randomized, open-labeled comparison of oral budesonide versus prednisone in children 8-18 years of age (weighing &gt;20 kg) with active Crohn&rsquo;s disease, 19 children (mean age: 13.8 &plusmn; 2.4 years) received budesonide 9 mg/day (divided into 3 doses per day) for 8 weeks, followed by 6 mg/day for 1 week and 3 mg/day for 1 week; remission rates were similar for budesonide versus prednisone; adverse effect were less with budesonide (Levine, 2003). In a randomized, double-blind, dipylidium controlled, comparative study of oral budesonide versus prednisolone in children 6-16 years of age with active Crohn&rsquo;s disease, 22 patients received budesonide 9 mg/day (given once daily in the morning) for 8 weeks, followed by 6 mg/day for 4 weeks; remission rates were similar for budesonide versus prednisolone; a trend existed for prednisolone to be more effective; significantly fewer adverse effects and less adrenal suppression were seen in the budesonide group (Escher, 2004). In a randomized placebo-controlled trial comparing two oral budesonide dosing regimens in 70 patients 10-19 years of age with mild or moderately active Crohn&rsquo;s disease, 35 patients (mean age: 13.6 years &plusmn; 2.8 years) received 9 mg/day for 7 weeks followed by 6 mg/day for 3 weeks; 35 patients (mean age: 14.4 years &plusmn; 2.5 years) received 12 mg/day for 4 weeks, then 9 mg/day for 3 weeks, followed by 6 mg/day for 3 weeks; remission rates were not statistically different; however, there was a trend for higher remission rates in the higher dose group; adverse effects were similar between the two groups (Levine, 2009). Further studies are needed to establish optimal dosing regimen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Budesonide capsules (Entocort&trade; EC) contain granules in an methylcellulose matrix; the granules are coated with a methacrylic acid polymer to protect from dissolution in the stomach; the coating dissolves at a pH &gt;5.5 (duodenal pH); the methylcellulose matrix controls the release of drug in a time-dependent manner (until the drug reaches the ileum and ascending colon).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The manufacturer of Pulmicort&reg; is replacing the Turbuhaler&reg; delivery system with a new device, the Flexhaler&reg;. The new  inhalation system is available in two strengths (180 mcg/inhalation and 90 mcg/inhalation) and will include an advanced indicator which will allow users to estimate the doses remaining in the device. Because the Turbuhaler&reg; will continue to be used until current devices are exhausted, this monograph retains dosing for both products.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Escher JC and the European Collaborative Research Group on Budesonide in Paediatric IBD, \"Budesonide Versus Prednisolone for the Treatment of Active Crohn's Disease in Children: A Randomized, Double-Blind, Controlled, Multicenter Trial,\"",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2004, 16(1):47-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21064/abstract-text/15095852/pubmed\" id=\"15095852\" target=\"_blank\">",
"        15095852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine A, Broide E, Stein M, et al, &ldquo;Evaluation of Oral Budesonide for Treatment of Mild and Moderate Exacerbations of Crohn's Disease in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 140(1):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21064/abstract-text/11815767/pubmed\" id=\"11815767\" target=\"_blank\">",
"        11815767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine A, Kori M, Dinari G, et al, \"Comparison of Two Dosing Methods for Induction of Response and Remission With Oral Budesonide in Active Pediatric Crohn's Disease: A Randomized Placebo-Controlled Trial,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2009, 15(7):1055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21064/abstract-text/19229988/pubmed\" id=\"19229988\" target=\"_blank\">",
"        19229988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine A, Weizman Z, Broide E, et al, \"A Comparison of Budesonide and Prednisone for the Treatment of Active Pediatric Crohn Disease,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2003, 36(2):248-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21064/abstract-text/12548062/pubmed\" id=\"12548062\" target=\"_blank\">",
"        12548062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), \"Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,\" Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at:",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szefler SJ, \"A Review of Budesonide Inhalation Suspension in the Treatment of Pediatric Asthma,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(2):195-206.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/36/21064/abstract-text/11213857/pubmed\" id=\"11213857\" target=\"_blank\">",
"        11213857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15946 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21064=[""].join("\n");
var outline_f20_36_21064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998594\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586184\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586284\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998744\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998596\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586344\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586244\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586185\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998654\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586224\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586226\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586225\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998671\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998672\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998645\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998646\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586345\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586245\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586246\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586247\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586346\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10586347\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/55/19317?source=related_link\">",
"      Budesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8116?source=related_link\">",
"      Budesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=related_link\">",
"      Budesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10873?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21065="Causes of metabolic myopathies";
var content_f20_36_21065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of metabolic myopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21065/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21065/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21065/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/36/21065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic myopathies have underlying deficiencies of energy production in muscle due to a wide variety of defects. These include defects in lipid glycogen and glucose metabolism, and other metabolic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the myopathies resulting from disorders of lipid metabolism is presented in this review. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency syndromes",
"     </li>",
"     <li>",
"      Fatty acid transport defects",
"     </li>",
"     <li>",
"      Defects of beta-oxidation enzymes",
"     </li>",
"     <li>",
"      Myoadenylate deaminase deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of the myopathies resulting from mitochondrial defects and from nonlysosomal and lysosomal glycogenoses are presented elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An overview of the clinical manifestations resulting from a metabolic myopathy and the approach to the patient suspected of having a metabolic myopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARNITINE DEFICIENCY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three different forms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency syndrome have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary muscle",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with lipid myopathy, which was first described in 1973 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with hepatic encephalopathy and myopathy, reported first in 1975 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with progressive cardiomyopathy, initially described in 1981 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many cases initially diagnosed as \"primary muscle",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency\" were eventually proven to be cases of secondary carnitine deficiency. Because of overlap in the clinical manifestations of the",
"    <span class=\"nowrap\">",
"     hepatic/myopathic",
"    </span>",
"    and cardiac forms, some experts do not distinguish between these forms or acknowledge them as separate; they consider systemic carnitine deficiency as a single entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary muscle carnitine deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attribution of specific symptoms to primary muscle",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency is confounded by the inclusion in most early reports of presumed primary muscle carnitine deficiency of patients with defects of intramitochondrial enzymes of beta-oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Most patients presented with the following symptoms and laboratory findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progressive proximal limb, trunk, and facial weakness, sometimes fluctuating, starting in childhood",
"     </li>",
"     <li>",
"      Lipid storage myopathy",
"     </li>",
"     <li>",
"      Very low",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      levels in skeletal muscle",
"     </li>",
"     <li>",
"      Variable plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      levels, usually normal or near normal",
"     </li>",
"     <li>",
"      Normal esterified",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      in plasma",
"     </li>",
"     <li>",
"      Normal liver or heart",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"     </li>",
"     <li>",
"      Variably increased serum creatine kinase values",
"     </li>",
"     <li>",
"      Myopathic findings on electromyography",
"     </li>",
"     <li>",
"      Slowly progressive course",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True primary muscle",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency is difficult to differentiate clinically from systemic carnitine deficiency, because non-muscle tissues, such as liver or heart, are usually not easily available for adequate biochemical study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/7\">",
"     7",
"    </a>",
"    ]. Oil red O staining of frozen muscle biopsy sections shows severe triglyceride storage, presumably related to an autosomal recessive muscle-specific biochemical defect involving the active transport of carnitine from blood into muscle. Such a defect, however, has not been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/8\">",
"     8",
"    </a>",
"    ]. Instead, many patients have secondary muscle carnitine deficiency due to a tissue-specific defect involving the short-chain isoform of acyl-CoA dehydrogenase (SCAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of patients with primary muscle",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (2 to 6 g per day) has been clinically beneficial. However, this regimen does not replenish muscle carnitine stores [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary systemic carnitine deficiency with hepatic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency with hepatic encephalopathy is a group of conditions that affect carnitine metabolism, thereby resulting in depletion of tissue and body fluid carnitine. The existence of a primary systemic carnitine deficiency has been debated, because a number of patients initially reported with systemic carnitine deficiency have subsequently been diagnosed as having defects of beta-oxidation enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/6\">",
"     6",
"    </a>",
"    ], such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD). These defects result in secondary carnitine deficiency and in dicarboxylic aciduria, which is prominent during metabolic crises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical and laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with Reye syndrome-like encephalopathy in association with hepatomegaly, hyperammonemia, hypoketotic hypoglycemia, elevation of liver enzymes, and reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    levels in plasma, muscle, liver, and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/11\">",
"     11",
"    </a>",
"    ]. Infants with primary systemic carnitine deficiency have had mild weakness and hypotonia, but no evidence of an overt myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolic crises in systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency are nonketotic, in contrast to idiopathic Reye syndrome, in which there is associated ketoacidosis. Although free carnitine levels are reduced in plasma and several tissues, the levels of esterified carnitine are higher than normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency have responded to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/3\">",
"     3",
"    </a>",
"    ]; however, this therapy has been ineffective in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic carnitine deficiency with cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency present with a lipid myopathy and cardiomyopathy (dilated cardiomyopathy or endocardial fibroelastosis), and occasionally hypoketotic hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]; ketoacidosis does not occur because fatty acids cannot be converted to ketoacids in the liver. Mutations in the SLC22A5 gene that encodes a sodium-ion dependent carnitine transporter protein named OCTN2 appear to be responsible for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/16\">",
"     16",
"    </a>",
"    ]. The cardiomyopathy is progressive and can lead to death if not treated. Affected infants may be hypotonic and show delayed gross motor development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    content in the muscle, heart, liver, and plasma of affected patients is very low. As an example, total and free carnitine levels in plasma are less than 10 percent of normal; carnitine esters are not increased.",
"   </p>",
"   <p>",
"    Lipid storage may be observed in pathologic specimens of skeletal muscle, heart, and liver. Gas chromatography-mass spectroscopy analysis of urine does not reveal dicarboxylic aciduria. However, the excretion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in the urine is increased significantly due to a defect in renal tubular reabsorption of filtered carnitine. Renal wasting of carnitine results in low serum levels and diminished hepatic uptake of carnitine by passive diffusion, which impairs ketogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis can be documented by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    uptake studies in cultured skin fibroblasts and confirmed with detection of recessive mutations in the carnitine transporter SLC22A5 (OCTN2) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The detection of low",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    levels in infants by newborn screening has lead to the identification of systemic primary carnitine deficiency in asymptomatic mothers of these children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/20\">",
"     20",
"    </a>",
"    ]. Affected mothers were compound heterozygotes or homozygotes for missense mutations. These findings expand the phenotypic spectrum of OCTN2 transporter defects from metabolic decompensation in infancy to asymptomatic adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated patients die of heart failure early in life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients respond dramatically to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/21\">",
"     21",
"    </a>",
"    ]. The usual dose is 2 to 6 grams of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    daily in adults, or 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four divided doses in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Secondary carnitine deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency has been described with the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Organic acidurias, such as propionic acidemia, methylmalonic aciduria, isovaleric aciduria, methylglutaconic aciduria, and glutaric aciduria type I.",
"     </li>",
"     <li>",
"      Mitochondrial respiratory chain defects",
"     </li>",
"     <li>",
"      Methylene tetrahydrofolate reductase deficiency",
"     </li>",
"     <li>",
"      Renal Fanconi syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic hemodialysis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"       \"Carnitine metabolism in renal disease and dialysis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/23\">",
"       23",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , and pivampicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/24\">",
"       24",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link\">",
"       \"Muscle disease in HIV-infected patients\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FATTY ACID TRANSPORT DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disorders of fatty acid transport include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      palmitoyltransferase I deficiency",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      palmitoyltransferase II deficiency",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      acylcarnitine translocase defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These defects are not usually associated with abnormal dicarboxylic aciduria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/25\">",
"     25",
"    </a>",
"    ]. This finding may be due principally to the failure of long-chain dicarboxylic acids formed by microsomal omega-oxidation to enter the mitochondria, where they are converted into shorter species and then excreted in urine. However, the absence of abnormal dicarboxylic aciduria in these disorders is not universal, since such findings have been reported in a single case of severe infantile CPT II deficiency and in a case of CPT I deficiency presenting with a Reye-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Carnitine acylcarnitine translocase and carnitine palmitoyltransferase I defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In CPT I and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    acylcarnitine translocase defects, the onset of the following symptoms occurs in infancy or early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      acylcarnitine translocase deficiency, both heart and skeletal muscle involvement is observed. Patients therefore present with progressive hypertrophic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dilated cardiomyopathy, and also skeletal muscle involvement. The initial manifestations are usually severe hypoketotic hypoglycemia and ventricular arrhythmias.",
"     </li>",
"     <li>",
"      In patients with CPT I deficiency, a Reye-like syndrome picture and renal tubular acidosis have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/30\">",
"       30",
"      </a>",
"      ]. Life-threatening hypoketotic hypoglycemia may develop. Muscle symptoms are not present. Serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      levels are normal or increased with a high",
"      <span class=\"nowrap\">",
"       free/total",
"      </span>",
"      ratio. Urine dicarboxylic acids are not increased. The diagnosis can be confirmed by detecting mutations in the CPT1A gene; the testing is clinically available.",
"     </li>",
"     <li>",
"      Adult-onset myopathy has been described in a single individual of Inuit origin and linked to CPT I deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy in pregnant female carriers due to homozygosity for a CPT1A gene mutation in the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In either condition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation has not been therapeutic. In one case report, a patient with a homozygous T314I mutation in the CPT1A protein responded to a low-fat diet with nighttime uncooked cornstarch feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/33\">",
"     33",
"    </a>",
"    ]. Pregnant women who are carriers should be monitored for acute fatty liver of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carnitine palmitoyltransferase II deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of affected individuals are homozygous or compound heterozygotes for mutations in the CPT2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/34\">",
"     34",
"    </a>",
"    ]. The two most common gene defects, S113L and R503C, may cause disease in heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/35\">",
"     35",
"    </a>",
"    ]. In general, missense mutations cause isolated muscle disease (eg, so-called \"mild mutations\" such as S113L), whereas truncating and homozygous mutations are associated with the severe infantile form of CPT II deficiency (eg, \"severe mutations\"). The occurrence of symptoms in patients with only one mutant allele suggests either incomplete detection of mutations or that these patients are symptomatic heterozygous carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/36\">",
"     36",
"    </a>",
"    ]. Compound heterozygosity for a \"mild\" and a \"severe\" mutation may result in either mild muscle disease or the severe lethal multisystemic form [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Severe infantile form",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with severe infantile CPT II deficiency typically present with a Reye-like syndrome characterized by hepatomegaly, hypoketotic hypoglycemia, elevated serum aminotransferases, elevated serum CK, cardiomegaly, cardiac arrhythmias, and lipid storage in heart, skeletal muscle, and other tissues. In these cases, the CPT II activity in cultured fibroblasts was less than 10 percent of control values [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/26,39,40\">",
"     26,39,40",
"    </a>",
"    ]. By comparison, in classic milder CPT II deficiency, there is at least 10 percent residual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/41\">",
"     41",
"    </a>",
"    ]. Antenatal diagnosis CPT II deficiency has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Myopathic form",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately two-thirds of patients with CPT II, the initial intermittent symptoms are noted during the first or second decade of life; in some patients, however, symptoms appear as late as the fifth decade [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of the myopathic form of CPT II consist of myalgias, muscle stiffness or tenderness, weakness, fatigue, and, in some cases, myoglobinuria. The myoglobinuria may lead to acute renal failure or respiratory insufficiency (requiring mechanical ventilation), or may be associated with hyperkalemia and hypocalcemia leading to cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In a report of 28 patients, exercise-induced myalgia was the most common symptom and generally began in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/46\">",
"     46",
"    </a>",
"    ]. Acute muscle contractures or cramps do not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/47\">",
"     47",
"    </a>",
"    ]. Myoglobinuria mostly occurred in adolescence or early adulthood, however myoglobinuria was not seen in five patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients usually develop symptoms and signs after prolonged exertion (commonly more than 30 minutes). Similar clinical manifestations may also be induced by fasting, exposure to cold, viral infections, fever, or even emotional distress. Other factors that may induce rhabdomyolysis are general anesthesia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    . Affected individuals do not show reduced tolerance to brief, intense isometric exercise; in addition, they do not experience a \"second-wind\" or \"out-of-wind\" phenomenon.",
"   </p>",
"   <p>",
"    Although uncommon, persistent proximal weakness has been described in a few patients following repeated episodes of rhabdomyolysis. No fixed cardiomyopathy has been described; in between attacks, the physical examination reveals no evidence of weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At rest and between episodes of myoglobinuria, the serum CK level is usually normal. However, prolonged exercise and prolonged fasting may increase the serum CK level.",
"   </p>",
"   <p>",
"    Additional laboratory findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum triglycerides and cholesterol may be elevated in some but not all patients",
"     </li>",
"     <li>",
"      Serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      is usually low",
"     </li>",
"     <li>",
"      The ischemic forearm exercise test is normal with respect to lactate and ammonia responses",
"     </li>",
"     <li>",
"      Electromyography is normal between attacks",
"     </li>",
"     <li>",
"      Muscle specimens obtained several months after episodes of myoglobinuria are normal",
"     </li>",
"     <li>",
"      Glycogen content is normal, and there is either no or only very slight lipid excess in type 1 fibers",
"     </li>",
"     <li>",
"      In most but not all patients, fasting ketogenesis is abnormal; as an example, a 38 to 72 hour fast induces no rise or partial rise in ketone bodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is confirmed by a combination of enzyme assay and genetic testing (targeted mutation analysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequencing of the entire gene). Recommended targeted DNA analysis tests includes both the common S113L mutation and the less common mutations (eg, P50H, Q413fs-F448L).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged aerobic exercise for more than 30 minutes, prolonged fasting, and cold exposure should be avoided to reduce the risk of muscle pain and rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/25\">",
"     25",
"    </a>",
"    ]. Once myoglobinuria occurs, it should be treated to help prevent intrarenal crystallization of myoglobin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary management is the mainstay of treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high-carbohydrate (70 to 75 percent), low-fat (10 to 15 percent), protein (15 percent) diet, frequent meals, and extra carbohydrate intake before sustained exercise appear to improve exercise intolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternatively, the triheptanoin (anaplerotic) diet appears promising [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/50\">",
"       50",
"      </a>",
"      ]. One study evaluated seven patients (10 to 55 years old) with CPT II deficiency who were started on the triheptanoin diet [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/51\">",
"       51",
"      </a>",
"      ]. The average daily percent composition was carbohydrate 37, fat 20, protein 13, and triheptanoin 30. An extra dose of triheptanoin was recommended 30 minutes before strenuous exercise. The following results were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/51\">",
"       51",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      None of the patients experienced rhabdomyolysis or hospitalizations while on the diet",
"     </li>",
"     <li>",
"      All returned to normal levels of physical activity, including strenuous sports, and exercise restrictions were no longer necessary",
"     </li>",
"     <li>",
"      The diet was well-tolerated and without significant side effects",
"     </li>",
"     <li>",
"      During a period of dietary noncompliance, two patients developed rhabdomyolysis with strenuous exercise; after returning to the triheptanoin diet, both were able to tolerate exercise again without restriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacologic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    may be beneficial for mild CPT II deficiency. In a case series, six adults with CPT II deficiency who were treated with bezafibrate (600 mg daily in three divided doses) showed increased muscle cell fatty acid oxidation and improvement in some self-assessed measures of physical functioning and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/52\">",
"     52",
"    </a>",
"    ]. Larger studies are needed to confirm whether bezafibrate is effective for CPT II deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DEFECTS OF BETA-OXIDATION ENZYMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intramitochondrial beta-oxidation defects involve the following enzymes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long-chain acyl-CoA dehydrogenase (LCAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Medium-chain acyl-CoA dehydrogenase (MCAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Short-chain acyl-CoA dehydrogenase (SCAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Very long-chain acyl-CoA dehydrogenase (VLCAD)",
"     </li>",
"     <li>",
"      Short-chain 3- hydroxyacyl-CoA dehydrogenase (SCHAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein (ETF)",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein-coenzyme Q oxidoreductase (ETF-CoQ)",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein dehydrogenase (ETFDH)",
"     </li>",
"     <li>",
"      Trifunctional enzyme",
"     </li>",
"     <li>",
"      HMG-CoA lyase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with defects in these enzymes may present similarly; however, there are differentiating features. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomyopathy is more common in the long-chain defects (eg, LCAD, VLCAD, trifunctional enzymes), but it has also been described in a single case of SCHAD deficiency.",
"     </li>",
"     <li>",
"      Transient hepatic dysfunction has been documented in most intramitochondrial enzymatic defects at times of catabolic crisis. In severe CPT II, LCAD, VLCAD, and trifunctional enzyme deficiencies, persistent hepatic dysfunction has been documented.",
"     </li>",
"     <li>",
"      Myopathy has been described in all intramitochondrial beta-oxidation defects with the exception of HMG-CoA lyase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple acyl-CoA dehydrogenase deficiency (MADD), or glutaric aciduria type II, is related to recessive mutations in the genes encoding the two subunits of ETF (ETFA and ETFB) or ETFDH. The symptoms vary from mild weakness and fatigue to severe with clinical features including metabolic crises, marked muscle weakness and exercise intolerance, hypotonia, hepatomegaly, &ldquo;sweaty feet&rdquo; odor, congenital polycystic kidneys, proximal tubular damage and neonatal death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/60\">",
"       60",
"      </a>",
"      ]. Associated secondary muscle coenzyme Q10 deficiency, primarily in adulthood, has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/47\">",
"       47",
"      </a>",
"      ], but it does not occur in all affected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Trifunctional enzyme deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trifunctional enzyme of beta-oxidation is a mitochondrial multi-enzyme complex with long-chain dehydrogenase, hydrolase, and thiolase activity. After MCAD deficiency, it is the most common fatty acid oxidation defect.",
"   </p>",
"   <p>",
"    Trifunctional enzyme deficiency presents in children as hypoketotic hypoglycemia, generalized metabolic disturbance with a Reye-like syndrome picture, cardiomyopathy, hypotonia, liver disease with fatty infiltration and cirrhosis, leading to death before the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. However, a deficiency of this enzyme may not be universally fatal. As an example, in a family with eight adult brothers and sisters, one affected individual had episodes of recurrent rhabdomyolysis plus peripheral sensory axonal polyneuropathy, and a second brother had only peripheral sensory neuropathy. Neither sibling had fixed muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/64\">",
"     64",
"    </a>",
"    ]. In another study of 11 patients followed through adolescence and adulthood, clinical features included infantile-onset progressive peripheral neuropathy and episodic exercise or fasting-induced rhabdomyolysis that was accompanied by respiratory failure in five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain types of treatment may be beneficial for specific fatty acid beta-oxidation defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Riboflavin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of ETF or ETF-CoQ deficiency (MADD) are responsive to treatment with riboflavin at a dose of 50 mg three times a day in young children, and 100 mg three times a day in older children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    uptake defects with cardiomyopathy, carnitine supplementation may be therapeutic. The usual dose is 2 to 6 gm per day in adults and 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four divided doses in children. There is no objective evidence that carnitine supplementation is beneficial in cases of intramitochondrial beta-oxidation defects with secondary carnitine deficiency. In fact, it appears that carnitine administration may be deleterious in long-chain fatty acid oxidation defects, as long-chain acylcarnitines may have a detergent effect on membranes and be arrhythmogenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Medium-chain triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medium-chain triglycerides (MCT) can be used in patients with long-chain fatty acid oxidation defects, because medium-chain fatty acids can enter mitochondria and thus circumvent the block in long-chain fatty acid oxidation. The dose of MCT oil is 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day in three divided doses, which can be gradually increased to 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Excess MCT oil, however, can be converted into long-chain fats in adipocytes, which limits the effectiveness of this treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H124915806\">",
"    <span class=\"h3\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with multiple acyl-CoA dehydrogenase deficiency and secondary coenzyme Q10 deficiency due to mutations in ETFDH have responded to coenzyme Q10 supplementation as well as riboflavin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/66\">",
"     66",
"    </a>",
"    ]. However, administration of riboflavin and carnitine as first-line treatment is suggested by some experts because not all patients with ETFDH deficiency have secondary coenzyme Q10 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179423868\">",
"    <span class=\"h1\">",
"     NEUTRAL LIPID STORAGE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the genes encoding two triglyceride lipases cause generalized lipid storage myopathy, one associated with ichthyosis (Chanarin-Dorfman syndrome, also called neutral lipid storage disease with ichthyosis or NLSDI), the other presenting with juvenile-onset weakness (neutral lipid storage disease with myopathy or NLSDM) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Chanarin-Dorfman syndrome (NLSDI) is caused by mutations in the ABHD5 gene (also called CGI-58) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/68\">",
"     68",
"    </a>",
"    ]; patients present with congenital ichthyosiform erythroderma, hepatomegaly, lipid droplets in blood granulocytes (known as the Jordan anomaly) and increased levels of serum creatine kinase and liver enzymes. A subset of patients with NLSDI has muscle weakness.",
"   </p>",
"   <p>",
"    Mutations in the PNPLA2 gene have been identified in patients with neutral lipid storage disease with myopathy (NLSDM) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/69\">",
"     69",
"    </a>",
"    ]. In NLSDM, the onset of weakness is usually late, after the first decade. One reported patient had no weakness despite extensive lipid storage and markedly elevated creatine kinase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MYOADENYLATE DEAMINASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoadenylate deaminase deficiency is probably the most common metabolic myopathy. Myoadenylate deaminase converts adenosine monophosphate to inosine monophosphate and ammonia. This enzyme has three tissue-specific subunits, E (erythrocyte), L (liver), and M (muscle). The gene that encodes for the M subunit (AMPD1) maps to the short arm of chromosome 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/71\">",
"     71",
"    </a>",
"    ]. Myoadenylate deaminase exists as an M homotetramer in human adult muscle. Pathogenic homozygous or heterozygous mutations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]; the heterozygous state is common and is found in approximately 10 percent of Caucasians and individuals of African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/72,76\">",
"     72,76",
"    </a>",
"    ]. However, many individuals are asymptomatic, possibly because of alternative splicing patterns involving exon 2 of AMPD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific treatment for symptomatic myoadenylate deaminase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoadenylate deaminase deficiency is detected in approximately 1 to 3 percent of muscle biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/78\">",
"     78",
"    </a>",
"    ]. Classic or primary myoadenylate deaminase deficiency is characterized by dynamic symptoms related to exertion, and consists primarily of muscle aches and cramps which are sometimes very mild and poorly defined; it can also present with myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myoadenylate deaminase deficiency has also been noted in patients with other myopathies, such as Duchenne or Becker muscular dystrophy, phosphorylase deficiency, spinal muscular atrophy, or amyotrophic lateral sclerosis. In the latter group of patients, the myoadenylate deaminase deficiency appears to be secondary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on laboratory examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resting serum creatine kinase level is usually normal",
"     </li>",
"     <li>",
"      Electromyography is normal in most cases, or may show nonspecific myopathic changes",
"     </li>",
"     <li>",
"      Muscle biopsy is histologically normal, but myoadenylate deaminase deficiency can be detected by immunohistochemistry [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/82\">",
"       82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The forearm ischemic exercise test shows a normal lactate curve, but no increase in the ammonia level or inosine monophosphate",
"     </li>",
"     <li>",
"      Molecular genetic testing may reveal homozygosity or compound heterozygosity for AMPD1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21065/abstract/72-75\">",
"       72-75",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MITOCHONDRIAL DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mitochondrial diseases present with myopathic symptoms or signs that are usually progressive, but dynamic symptoms may also be observed. The clinical aspects of the myopathies resulting from mitochondrial defects are presented elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A detailed discussion concerning renal disease in patients with mitochondrial defects is also found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link\">",
"     \"Renal involvement in the mitochondrial cytopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32366614\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic myopathies have underlying deficiencies of energy production in muscle due to a wide variety of defects. These include defects in lipid glycogen and glucose metabolism, and other metabolic pathways.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three different forms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency syndrome have been described (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Carnitine deficiency syndromes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary muscle",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with lipid myopathy (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary muscle carnitine deficiency'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with hepatic encephalopathy and myopathy (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Primary systemic carnitine deficiency with hepatic encephalopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency associated with progressive cardiomyopathy (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Systemic carnitine deficiency with cardiomyopathy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disorders of fatty acid transport include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      acylcarnitine translocase defects and Carnitine palmitoyltransferase I deficiency (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Carnitine acylcarnitine translocase and carnitine palmitoyltransferase I defects'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      palmitoyltransferase II deficiency (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Carnitine palmitoyltransferase II deficiency'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intramitochondrial beta-oxidation defects involve the following enzymes (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Defects of beta-oxidation enzymes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Long-chain acyl-CoA dehydrogenase (LCAD)",
"     </li>",
"     <li>",
"      Medium-chain acyl-CoA dehydrogenase (MCAD)",
"     </li>",
"     <li>",
"      Short-chain acyl-CoA dehydrogenase (SCAD)",
"     </li>",
"     <li>",
"      Very long-chain acyl-CoA dehydrogenase (VLCAD)",
"     </li>",
"     <li>",
"      Short-chain 3- hydroxyacyl-CoA dehydrogenase (SCHAD)",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein (ETF)",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein-coenzyme Q oxidoreductase (ETF-CoQ)",
"     </li>",
"     <li>",
"      Electron transfer flavoprotein dehydrogenase (ETFDH)",
"     </li>",
"     <li>",
"      Trifunctional enzyme (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Trifunctional enzyme deficiency'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      HMG-CoA lyase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the genes encoding two triglyceride lipases cause generalized lipid storage myopathy, one associated with ichthyosis (Chanarin-Dorfman syndrome, also called neutral lipid storage disease with ichthyosis), the other presenting with juvenile-onset weakness (neutral lipid storage disease with myopathy). (See",
"      <a class=\"local\" href=\"#H179423868\">",
"       'Neutral lipid storage diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myoadenylate deaminase converts adenosine monophosphate to inosine monophosphate and ammonia. Myoadenylate deaminase deficiency is detected in approximately 1 to 3 percent of muscle biopsy specimens. Classic or primary myoadenylate deaminase deficiency is characterized by dynamic symptoms related to exertion, and consists primarily of muscle aches and cramps which are sometimes very mild and poorly defined; it can also present with myoglobinuria. Asymptomatic or secondary myoadenylate deaminase deficiency is common. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Myoadenylate deaminase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most mitochondrial diseases present with myopathic symptoms or signs that are usually progressive, but dynamic symptoms may also be observed. The clinical aspects of the myopathies resulting from mitochondrial defects are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"       \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/1\">",
"      Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/2\">",
"      Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/3\">",
"      Karpati G, Carpenter S, Engel AG, et al. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 1975; 25:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/4\">",
"      Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1981; 305:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/5\">",
"      De Vivo DC, Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990; 5:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/6\">",
"      Stanley CA. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv Pediatr 1987; 34:59.",
"     </a>",
"    </li>",
"    <li>",
"     Scholte, H, de Jonge, P. Metabolism, function and transport of carnitine in health and disease. In: Carnitin in der Medizin, Gitzelman, R, Baerlocker, K, Steinmann, B (Eds), Schattauer, Stuttgart, Germany 1987. p.22.",
"    </li>",
"    <li>",
"     DiDonato, S, Taroni, F. Disorders of lipid metabolism. In: The molecular and genetic basis of neurological disease, Rosenberg, RN, Prusiner, SB, DiMauro, S, et al (Eds), Butterworth-Heinemann, Boston 2003. p.591.",
"    </li>",
"    <li>",
"     DiMauro, S, De Vivo, DC. Diseases of carbohydrate, fatty acid and mitochondrial metabolism. In: Basic neurochemistry: molecular, cellular and medical aspects, 7th, Siegel, GJ, Albers, RW, Brady, ST, Price, DL (Eds), Academic Press, Boston 2007. p.695.",
"    </li>",
"    <li>",
"     Engel, A. Carnitine deficiency syndromes and lipid storage myopathies. In: Myology, Engel, A, Banker, B (Eds), McGraw-Hill, New York, NY 1986. p.1663.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/11\">",
"      Coates PM, Hale DE, Stanley CA, Glasgow AM. Systemic carnitine deficiency simulating Reye syndrome. J Pediatr 1984; 105:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/12\">",
"      Cruse RP, Di Mauro S, Towfighi J, Trevisan C. Familial systemic carnitine deficiency. Arch Neurol 1984; 41:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/13\">",
"      Hale DE, Cruse RP, Engel A. Familial systemic carnitine deficiency. Arch Neurol 1985; 42:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/14\">",
"      Cornelio F, Di Donato S, Peluchetti D, et al. Fatal cases of lipid storage myopathy with carnitine deficiency. J Neurol Neurosurg Psychiatry 1977; 40:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/15\">",
"      Chapoy PR, Angelini C, Brown WJ, et al. Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med 1980; 303:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/16\">",
"      Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/17\">",
"      Lamhonwah AM, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002; 111:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/18\">",
"      Melegh B. [The human OCTN2 carnitine transporter and its mutations]. Orv Hetil 2004; 145:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/19\">",
"      Wang Y, Korman SH, Ye J, et al. Phenotype and genotype variation in primary carnitine deficiency. Genet Med 2001; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/20\">",
"      El-Hattab AW, Li FY, Shen J, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/21\">",
"      Cano A, Ovaert C, Vianey-Saban C, Chabrol B. Carnitine membrane transporter deficiency: a rare treatable cause of cardiomyopathy and anemia. Pediatr Cardiol 2008; 29:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/22\">",
"      Bernardini I, Rizzo WB, Dalakas M, et al. Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 1985; 75:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/23\">",
"      Ito M, Ikeda Y, Arnez JG, et al. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 1990; 1034:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/24\">",
"      Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989; 2:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/25\">",
"      Tein I. Metabolic myopathies. Semin Pediatr Neurol 1996; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/26\">",
"      Elpeleg ON, Joseph A, Branski D, et al. Recurrent metabolic decompensation in profound carnitine palmitoyltransferase II deficiency. J Pediatr 1993; 122:917.",
"     </a>",
"    </li>",
"    <li>",
"     Poll-The, B, Duran, M, Mousson, B, et al. Carnitine palmitoyltransferase I deficiency: Is there a diagnostic dicarboxylic aciduria? In: 30th Annual Symposium of the Society for the Study of Inborn Errors of Metabolism. Leuven, Scotland 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/28\">",
"      Stanley CA, Hale DE, Berry GT, et al. Brief report: a deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992; 327:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/29\">",
"      Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proc Natl Acad Sci U S A 1975; 72:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/30\">",
"      Falik-Borenstein ZC, Jordan SC, Saudubray JM, et al. Brief report: renal tubular acidosis in carnitine palmitoyltransferase type 1 deficiency. N Engl J Med 1992; 327:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/31\">",
"      Brown NF, Mullur RS, Subramanian I, et al. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res 2001; 42:1134.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett MJ, Narayan SB, Santani AB. Carnitine palmitoyltransferase 1A deficiency. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1527/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/33\">",
"      Stoler JM, Sabry MA, Hanley C, et al. Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation. J Inherit Metab Dis 2004; 27:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/34\">",
"      Taggart RT, Smail D, Apolito C, Vladutiu GD. Novel mutations associated with carnitine palmitoyltransferase II deficiency. Hum Mutat 1999; 13:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/35\">",
"      Rafay MF, Murphy EG, McGarry JD, et al. Clinical and biochemical heterogeneity in an Italian family with CPT II deficiency due to Ser 113 Leu mutation. Can J Neurol Sci 2005; 32:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/36\">",
"      Anichini A, Fanin M, Vianey-Saban C, et al. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency. Neurol Res 2011; 33:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/37\">",
"      Vladutiu GD, Quackenbush EJ, Hainline BE, et al. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr 2002; 141:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/38\">",
"      Isackson PJ, Bennett MJ, Lichter-Konecki U, et al. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2008; 94:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/39\">",
"      Demaugre F, Bonnefont JP, Colonna M, et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 1991; 87:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/40\">",
"      Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991; 325:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/41\">",
"      Olpin SE, Afifi A, Clark S, et al. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis 2003; 26:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/42\">",
"      Elpeleg ON, Hammerman C, Saada A, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 2001; 102:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/43\">",
"      Kilfoyle D, Hutchinson D, Potter H, George P. Recurrent myoglobinuria due to carnitine palmitoyltransferase II deficiency: clinical, biochemical, and genetic features of adult-onset cases. N Z Med J 2005; 118:U1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/44\">",
"      DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 1973; 182:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/45\">",
"      Uzel B, Altiparmak MR, Ataman R, Serdenge&ccedil;ti K. Acute renal failure due to carnitine palmitoyltransferase II deficiency. Neth J Med 2003; 61:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/46\">",
"      Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005; 62:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/47\">",
"      Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010; 10:118.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro, S, Papadimitriou, A. Carnitine palmitoyltransferase deficiency. In: Myology, Engel, A, Banker, B (Eds), McGraw-Hill, New York, NY 1986. p.1697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/49\">",
"      &Oslash;rngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003; 61:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/50\">",
"      Roe CR, Sweetman L, Roe DS, et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002; 110:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/51\">",
"      Roe CR, Yang BZ, Brunengraber H, et al. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008; 71:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/52\">",
"      Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009; 360:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/53\">",
"      Hale DE, Batshaw ML, Coates PM, et al. Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia. Pediatr Res 1985; 19:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/54\">",
"      Engel WK, Vick NA, Glueck CJ, Levy RI. A skeletal-muscle disorder associated with intermittent symptoms and a possible defect of lipid metabolism. N Engl J Med 1970; 282:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/55\">",
"      Stanley CA, Hale DE, Coates PM, et al. Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res 1983; 17:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/56\">",
"      Duran M, Hofkamp M, Rhead WJ, et al. Sudden child death and 'healthy' affected family members with medium-chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics 1986; 78:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/57\">",
"      Amendt BA, Greene C, Sweetman L, et al. Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients. J Clin Invest 1987; 79:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/58\">",
"      Tein I, De Vivo DC, Hale DE, et al. Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol 1991; 30:415.",
"     </a>",
"    </li>",
"    <li>",
"     Tein, I. Fatty acid oxidation and associated defects. In: Proceedings of the American Academy of Neurology. Seattle, WA. Madison, WI, Omnipress 1995. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/60\">",
"      Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008; 93:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/61\">",
"      Liang WC, Ohkuma A, Hayashi YK, et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord 2009; 19:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/62\">",
"      Jackson S, Bartlett K, Land J, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Res 1991; 29:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/63\">",
"      Jackson S, Kler RS, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest 1992; 90:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/64\">",
"      Schaefer J, Jackson S, Dick DJ, Turnbull DM. Trifunctional enzyme deficiency: adult presentation of a usually fatal beta-oxidation defect. Ann Neurol 1996; 40:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/65\">",
"      Spiekerkoetter U, Bennett MJ, Ben-Zeev B, et al. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/66\">",
"      Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007; 130:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/67\">",
"      DiMauro S, Garone C, Naini A. Metabolic myopathies. Curr Rheumatol Rep 2010; 12:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/68\">",
"      Bruno C, Bertini E, Di Rocco M, et al. Clinical and genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun 2008; 369:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/69\">",
"      Fischer J, Lef&egrave;vre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 2007; 39:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/70\">",
"      Akman HO, Davidzon G, Tanji K, et al. Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscul Disord 2010; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/71\">",
"      Sabina RL, Morisaki T, Clarke P, et al. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem 1990; 265:9423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/72\">",
"      Genetta T, Morisaki H, Morisaki T, Holmes EW. A novel bipartite intronic splicing enhancer promotes the inclusion of a mini-exon in the AMP deaminase 1 gene. J Biol Chem 2001; 276:25589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/73\">",
"      Abe M, Higuchi I, Morisaki H, et al. Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient. Neuromuscul Disord 2000; 10:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/74\">",
"      Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 1992; 89:6457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/75\">",
"      Morisaki H, Higuchi I, Abe M, et al. First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. Hum Mutat 2000; 16:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/76\">",
"      Sabina RL, Ogasawara N, Holmes EW. Expression of three stage-specific transcripts of AMP deaminase during myogenesis. Mol Cell Biol 1989; 9:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/77\">",
"      Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993; 91:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/78\">",
"      Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985; 33:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/79\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/80\">",
"      Baumeister FA, Gross M, Wagner DR, et al. Myoadenylate deaminase deficiency with severe rhabdomyolysis. Eur J Pediatr 1993; 152:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/81\">",
"      Sabina RL. Myoadenylate deaminase deficiency. A common inherited defect with heterogeneous clinical presentation. Neurol Clin 2000; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21065/abstract/82\">",
"      Fishbein WN, Griffin JL, Armbrustmacher VW. Stain for skeletal muscle adenylate deaminase. An effective tetrazolium stain for frozen biopsy specimens. Arch Pathol Lab Med 1980; 104:462.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6197 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21065=[""].join("\n");
var outline_f20_36_21065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32366614\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARNITINE DEFICIENCY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary muscle carnitine deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary systemic carnitine deficiency with hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical and laboratory features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic carnitine deficiency with cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Secondary carnitine deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FATTY ACID TRANSPORT DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Carnitine acylcarnitine translocase and carnitine palmitoyltransferase I defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carnitine palmitoyltransferase II deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Severe infantile form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Myopathic form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DEFECTS OF BETA-OXIDATION ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Trifunctional enzyme deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Riboflavin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Carnitine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Medium-chain triglycerides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H124915806\">",
"      - Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179423868\">",
"      NEUTRAL LIPID STORAGE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MYOADENYLATE DEAMINASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MITOCHONDRIAL DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32366614\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21066="Autism and chronic disease: Little evidence for thimerosal as a contributing factor";
var content_f20_36_21066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/36/21066/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/36/21066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, there appears to have been an increase in the number of cases of autism diagnosed in the United States and other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Rates of autistic spectrum disorders in studies from the late 1990s are consistently greater than 10 per 10,000, compared with 4 to 5 per 10,000 in previous decades [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/7\">",
"     7",
"    </a>",
"    ]. Active surveillance in the United States suggests a prevalence of approximately 1 in 90 eight-year-old children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H9#H9\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This real or perceived increase in autism cases has occurred at a time when there has been a significant increase in the number of recommended childhood vaccines. In the search for a causal relationship, parents of autistic children and some professionals have identified a temporal association between immunizations and the onset of more evident symptoms of autism in the second year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been suggested that certain vaccines (eg, measles, mumps, and rubella [MMR]) and vaccine constituents (eg, thimerosal) play a role in the development of autism and other chronic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research to prove or disprove a possible relationship between the various components of recommended childhood vaccines and chronic diseases such as autism is ongoing. However, to date, no scientific linkage has been established. The evidence for and against an association between thimerosal and autism and chronic disease will be presented here. The evidence for and against an association between vaccines and autism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of autism spectrum disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"     \"Clinical features of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPARENT INCREASE IN AUTISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, there appears to have been an increase in the number of cases of autism diagnosed in the United States and other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Much attention was generated when the California Department of Developmental Services reported a 210 percent increase in the number of persons with autism between 1987 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/1\">",
"     1",
"    </a>",
"    ]. Adequate explanation for the increase was not clear, though there was speculation that changes in diagnostic criteria and an increased awareness of the condition among health-care providers and developmental specialists may have been contributing factors. Subsequent reports analyzing data from cohorts of children with autism from regional developmental centers in California reached opposite conclusions about whether the apparent rise in cases of autism was attributable to changes in diagnostic criteria, misclassification, or in-migration to a generous service system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H8#H8\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparing studies with different case definitions, methods of case finding, and sample populations is problematic unless there is rigorous control for these variables, even when the studies being compared occur during the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/7\">",
"     7",
"    </a>",
"    ]. Systematic reviews of the epidemiologic studies of autism have found evidence that changes in case definition and increased awareness account for much of the apparent increase in the prevalence of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/7,18-20\">",
"     7,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thimerosal, or sodium ethylmercury thiosalicylate, is an organic compound that has been used as a preservative since the 1930s. Thimerosal has been used as a preservative in hepatitis B, diphtheria-tetanus-acellular-pertussis, and",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b (Hib) vaccines, as well as other vaccines that are no longer part of the routine childhood vaccination schedule for children in the United States. In the United States, Rh immune globulin also contained thimerosal until 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/21\">",
"     21",
"    </a>",
"    ]. The dose of ethylmercury per dose of vaccine has ranged from &lt;0.03 to 25 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/22\">",
"     22",
"    </a>",
"    ]. At such low doses, the only identified risk of thimerosal in humans has been a hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1999, the US Food and Drug Administration (FDA) released a statement that some infants who received thimerosal-containing vaccines at multiple visits could potentially receive cumulative doses of ethylmercury that would exceed Environmental Protection Agency (EPA) guidelines for methylmercury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. After the release of this statement, the American Academy of Pediatrics (AAP) and the US Public Health Service (USPHS) issued a joint statement recommending that thimerosal-containing vaccines be reduced or eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/27\">",
"     27",
"    </a>",
"    ]. The statement also recommended that, until thimerosal-free hepatitis B vaccines were available, the first dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    for infants of mothers seronegative for hepatitis B surface antigen (HBsAg) be delayed until the infants reached two to six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/USPHS",
"    </span>",
"    recommendation was taken as a precautionary measure, since there was no evidence of any harm caused by the low levels of mercury in the vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/29\">",
"     29",
"    </a>",
"    ]. An advisory committee to the World Health Organization in a 2002 report concluded that the continued use of thimerosal in vaccines was safe, particularly in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA statement and",
"    <span class=\"nowrap\">",
"     AAP/USPHS",
"    </span>",
"    recommendations led to concerns regarding a possible association between thimerosal and neurologic disability, including autism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/31\">",
"     31",
"    </a>",
"    ]. The neurotoxicity of mercury at high doses underlies these concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By July 2000, children in the United States had access to thimerosal-free hepatitis B, Hib, and diphtheria-tetanus-acellular-pertussis vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/33\">",
"     33",
"    </a>",
"    ]. Measles-mumps-rubella, varicella, inactivated polio, and pneumococcal conjugate vaccines never contained thimerosal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impact of controversy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When increased supplies of thimerosal-free",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    became available in September 1999, the USPHS recommended resumption of newborn hepatitis B immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/34\">",
"     34",
"    </a>",
"    ]. Despite the availability of thimerosal-free vaccine and the USPHS recommendation, there has been a decline in the routine administration of hepatitis B vaccine to newborns of HBsAg-negative mothers before discharge from the newborn nursery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By March 2000, in Wisconsin, the number of hospitals with written policies or standing orders for newborn hepatitis B vaccination fell from 81 to 10 percent, and routine immunization prior to discharge declined from 84 to 43 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Cook County, Illinois, there was a 35 percent decrease in the number of hospital nurseries offering routine HepB vaccine to neonates one year after the recommendation to resume immunization [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proportion of infants in the United States who received the first dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      at birth declined from 47 percent 7 to 12 months before the suspension to 33 percent one year after the suspension was lifted [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some hospitals misinterpreted the guideline and discontinued administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    to all newborns, resulting in delayed immunization of some infants born to HBsAg-positive mothers or mothers whose HBsAg status was unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/35,38-40\">",
"     35,38-40",
"    </a>",
"    ]. One such unvaccinated infant died from fulminant hepatitis B infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mercury toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of mercury is complex and is dependent on the form of mercury (methylmercury versus ethylmercury), the route of entry (ie, ingested versus injected), the dose, and the age at exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/32,41\">",
"     32,41",
"    </a>",
"    ]. Thimerosal contains 50 percent ethylmercury by weight and has a toxicologic profile that is thought to be similar to ethylmercury from other sources [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/42\">",
"     42",
"    </a>",
"    ]. The main route of environmental exposure to organic mercury (eg, methylmercury or ethylmercury) is through the consumption of predatory fish, particularly shark and swordfish. Clinically significant poisoning from mercury is unlikely if blood and urine concentrations are below 100",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"   </p>",
"   <p>",
"    Little",
"    is known about the pharmacokinetics of ethylmercury in human infants. One small study measured blood mercury concentration before and after administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    in 15 preterm and five term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/43\">",
"     43",
"    </a>",
"    ]. Mean mercury concentrations before vaccination were similar between both groups (0.54 and 0.04",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    respectively). However, mean mercury concentrations after vaccination were greater among the preterm infants (7.36 versus 2.24",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"   </p>",
"   <p>",
"    Two additional studies measured blood, urine, and stool mercury concentrations before and after vaccination of infants with thimerosal-containing vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In the larger of these studies, blood, urine, and stool mercury concentrations were measured 12 hours to 30 days after vaccination in 216 healthy infants with gestational age &gt;32 weeks (72 newborns, 72 two-month-olds, and 72 six-month-olds) who received thimerosal-containing vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mercury dose ranged from 12.5 to 32.5 mcg in the newborns, 37.5 to 57.5 mcg in the two-month-olds (with a cumulative dose between 50 and 90 mcg), and 37.5 to 57.5 mcg in the six-month-olds (with a cumulative dose between 112.5 and 162.5 mcg).",
"     </li>",
"     <li>",
"      Blood mercury levels peaked at 0.5 to 1 day after vaccination and returned to prevaccination levels within a few weeks. The estimated blood mercury half-life was calculated to be 3.7 days (95% CI 2.9-4.5).",
"     </li>",
"     <li>",
"      The maximal mean blood mercury levels were 5",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      3.6",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and 2.8",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in the newborns, two-month-olds, and six-month-olds, respectively.",
"     </li>",
"     <li>",
"      Prevaccination blood mercury levels in six-month-olds were not higher than those in two-month-olds, suggesting that exposure to thimerosal-containing vaccines does not result in an accumulation of mercury in the blood.",
"     </li>",
"     <li>",
"      For all infants, the concentration of mercury in the blood was less than the concentration that is thought to be safe in cord blood (29",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stool mercury levels peaked on day five after vaccination; maximal mean stool mercury levels were 19.1",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      37",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and 44.3",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in the newborns, two-month-olds, and six-month-olds, respectively.",
"     </li>",
"     <li>",
"      Mercury was virtually undetectable in urine in all samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies indicate that younger infants with lower body weights have higher blood mercury concentrations after immunization with thimerosal-containing vaccines than do older, heavier infants. However, the concentrations do not exceed those thought to be safe in cord blood. Furthermore, ethylmercury is rapidly eliminated from the blood of infants who receive thimerosal-containing vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Methylmercury versus ethylmercury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethylmercury (CH3CH2Hg+) and methylmercury (CH3Hg+) have similar chemical structures and similar initial distribution in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/32\">",
"     32",
"    </a>",
"    ]. At toxic doses, they cause similar damage to the brain. High-dose exposure to ethylmercury (&ge;3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can cause severe toxicity, including local necrosis, acute hemolysis, disseminated intravascular coagulation, acute tubular necrosis, and central nervous system injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/47-52\">",
"     47-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information regarding the clinical effects of low-dose exposure to mercury. The only studies describing low-dose exposure to organic mercury are those involving prenatal exposure to methylmercury from fish consumption in the Seychelles and Faroe Islands [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. The results of these studies are inconsistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies from the Faroe Islands, where mercury exposure was primarily through whale consumption [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/56\">",
"       56",
"      </a>",
"      ], report subtle and long-term cognitive deficits at methylmercury levels previously thought to be safe [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/55,57\">",
"       55,57",
"      </a>",
"      ]. However, children from these islands may have been exposed to additional toxins (eg, polychlorinated biphenyls) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of children from the Seychelles, evaluating more global outcomes, failed to find significant cognitive or behavioral effects in offspring of women with high fish consumption when other factors, such as social and environmental developmental modifiers and postnatal mercury exposure, were considered [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extrapolating the neurotoxic effects of low-dose methylmercury exposure to low-dose ethylmercury exposure is problematic because the two compounds have different half-lives (50 versus 7 days, respectively) and biologically distinct behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/42,60-62\">",
"     42,60-62",
"    </a>",
"    ]. Whereas methylmercury is actively transported across the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/63\">",
"     63",
"    </a>",
"    ], ethylmercury is not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. The transport of ethylmercury into the central nervous system is further hindered by its larger molecular size and rapid decomposition. The lack of transport of ethylmercury across the blood-brain barrier is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After equivalent doses of ethylmercury and methylmercury were administered to different groups of rodents, greater concentrations of mercury were detected in the blood than in the brain of the rodents that had received ethylmercury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/61,65\">",
"       61,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In experimental studies in rats, postnatal exposure to ethylmercury caused patchy damage in the cerebellar granule cell layer, whereas postnatal exposure to methylmercury caused diffuse abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with methylmercury, ethylmercury exposure produced more lesions of the spinal cord, skeletal muscle, and myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both methylmercury and ethylmercury have neurotoxic effects, methylmercury appears to be a more potent toxin, with a longer half-life and greater access to the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSSIBLE ASSOCIATION BETWEEN THIMEROSAL AND AUTISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because mercury is known to be a neurotoxin, the concern regarding the neurologic effects of thimerosal is a biologically plausible one [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. However, data regarding low-dose mercury toxicity are limited and primarily related to prenatal methylmercury, rather than postnatal ethylmercury, exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methylmercury versus ethylmercury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] hypothesize that autism is an expression of mercury poisoning. They base this hypothesis on their observations that mercury toxicity and autism appear to have similar clinical manifestations, that the apparent increase in the number of cases of autism parallels the increased exposure to thimerosal, and that a temporal association may be perceived between the onset of autism and immunization. These observations are discussed in detail and refuted below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Lack of evidence for association between thimerosal and autism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional concern regarding an association between thimerosal and autism stems from anecdotal and unpublished reports of improvement in children with autism and abnormal blood metal levels following chelation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/9,67-69\">",
"     9,67-69",
"    </a>",
"    ]. However, systematic review of the peer-reviewed literature found no publications reporting an abnormal burden of mercury or an excess of mercury in hair, urine, or blood of patients with autism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/70\">",
"     70",
"    </a>",
"    ], and published evidence that chelation therapy improves autism is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reports of an association between thimerosal and autism are derived from data from the Vaccine Adverse Event Reporting System (VAERS), a passive surveillance that relies on clinicians and others to voluntarily report possible vaccine adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/14,15,71\">",
"     14,15,71",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) issued a response to these reports, critiquing their methods and conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/41\">",
"     41",
"    </a>",
"    ]. Highlights of the AAP response include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VAERS data, although useful for generating hypotheses about causal associations, cannot be used to verify causal associations because of the lack of information about the comparison group (ie, the group of individuals who were immunized and did not report problems) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiologic studies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The method for calculation of thimerosal exposure was not revealed (necessary data for this calculation are not available in VAERS reports).",
"     </li>",
"     <li>",
"      The authors of the report make assumptions about possible exposure to thimerosal for early (1984-1985) and late (1990-1994) cohorts that are contrary to the timing of introduction of thimerosal-containing vaccines to the routine childhood immunization schedule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LACK OF EVIDENCE FOR ASSOCIATION BETWEEN THIMEROSAL AND AUTISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86482543\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research to prove or disprove a possible relationship between thimerosal and autism is ongoing. However, to date, no scientific linkage has been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristic features of mercury poisoning have little in common with those of autism (",
"      <a class=\"graphic graphic_table graphicRef68160 \" href=\"UTD.htm?31/59/32699\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although the hypothesis that thimerosal-containing vaccines can cause neurodevelopmental disorders, including autism, is biologically possible, the information upon which the hypothesis is based is indirect and incomplete, and the potential mechanisms are considered theoretical [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple large, well-designed epidemiologic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/4,73-77\">",
"       4,73-77",
"      </a>",
"      ] and systematic reviews [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64,67,72,78\">",
"       64,67,72,78",
"      </a>",
"      ] have found insufficient evidence to support an association between thimerosal-containing vaccines and autism or other developmental disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In its latest review, the Immunization Safety Review Committee of the Institute of Medicine concludes that the evidence favors rejection of a causal relationship between thimerosal-containing vaccines and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comparison of clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features, diagnosis, and treatment of mercury poisoning and autism are discussed in detail separately. A brief overview of the clinical manifestations of each disorder is provided here to highlight the differences between them (",
"    <a class=\"graphic graphic_table graphicRef68160 \" href=\"UTD.htm?31/59/32699\">",
"     table 1",
"    </a>",
"    ). The clinical features of autism are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common characteristic motor findings in high-dose mercury poisoning include ataxia, dysarthria, tremor, muscle pain, and weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/52,79,80\">",
"     52,79,80",
"    </a>",
"    ]. In contrast, the characteristic motor finding in children with autism is repetitive behavior, such as flapping, circling, or rocking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. Hypotonia has been noted in some infants with autism, and clumsiness in some cases of Asperger syndrome. However, other motor manifestations are uncommon. The presence of ataxia or dysarthria in a child whose behavior has autistic features should prompt a careful medical evaluation for an alternative or additional diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with mercury poisoning typically have dysarthric speech. In contrast, individuals with autism or an autism spectrum disorder (ASD) typically have delayed speech or echolalia.",
"   </p>",
"   <p>",
"    Sensory findings in mercury poisoning include bilateral visual field constriction, which is highly specific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/79-81\">",
"     79-81",
"    </a>",
"    ], and paresthesias. In addition, infants with mercury poisoning may have erythema and pain in the hands and feet from peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. Sensory findings in autism include decreased responsiveness to pain and hypersensitivity to other sensory stimuli, including sounds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, children with",
"    <span class=\"nowrap\">",
"     autism/ASD",
"    </span>",
"    may have \"sensory defensiveness\", which appears to be caused by abnormalities in central sensory processing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other manifestations of mercury poisoning include hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/85\">",
"     85",
"    </a>",
"    ], skin eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition, patients with mercury poisoning may have toxic psychosis or, in milder cases, nonspecific depression, anxiety, or irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Hypertension, rash, and thrombocytopenia are not features of autism or ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with prenatal or early childhood exposure to mercury typically have decreased head circumference [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/92\">",
"     92",
"    </a>",
"    ]. In contrast, patients with autism often have macrocephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/93-96\">",
"     93-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic findings in the brains of individuals who died as a result of mercury poisoning include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/66,97\">",
"     66,97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe atrophy and gliosis of the calcarine cortex",
"     </li>",
"     <li>",
"      Diffuse neuronal loss and gliosis of the auditory, motor, and sensory cortices",
"     </li>",
"     <li>",
"      Extensive cerebellar atrophy",
"     </li>",
"     <li>",
"      Demyelination of 9",
"      <sup>",
"       th",
"      </sup>",
"      and 10",
"      <sup>",
"       th",
"      </sup>",
"      cranial nerve roots",
"     </li>",
"     <li>",
"      Atrophy of the cerebellar granule cell layer with relative sparing of Purkinje cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The brains of autistic children examined at autopsy or with magnetic resonance imaging (MRI) are typically enlarged in weight and volume compared with those of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Additional findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/98,100,101\">",
"     98,100,101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unusually small, closely packed neurons and increased cell-packing density in portions of the limbic system, consistent with curtailment of development of this circuitry",
"     </li>",
"     <li>",
"      Reduction in the number of Purkinje cells in the cerebellum, primarily in the posterior inferior hemispheres",
"     </li>",
"     <li>",
"      Involvement of granule cells has rarely been reported",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Biologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causal association between thimerosal-containing vaccines and neurodevelopmental disorders, including autism, has not been established. Although biologic mechanisms for such an association have been proposed, the information upon which the hypotheses are based is indirect and incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/67\">",
"     67",
"    </a>",
"    ], and the potential mechanisms are considered theoretical [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose thimerosal exposure in humans has not been demonstrated to be associated with effects on the nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurodevelopmental effects have been demonstrated in some populations [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/55\">",
"       55",
"      </a>",
"      ] for prenatal but not postnatal exposures to low doses of methylmercury.",
"     </li>",
"     <li>",
"      Thimerosal exposure from vaccines has not been proven to result in mercury levels associated with toxic responses; after exposure to thimerosal-containing vaccines, ethylmercury appears to be rapidly eliminated from the blood of infants with gestational age &gt;32 weeks, with an estimated half-life of 3.7 days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no evidence that ethylmercury causes any of the pathophysiologic changes that are known to be associated with autism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epidemiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To determine whether thimerosal is associated with autism, it is necessary to compare the relative risk of developing autism among children who were and were not exposed to thimerosal. Such epidemiologic methods have been used to detect associations between the swine flu vaccine and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/102\">",
"     102",
"    </a>",
"    ], the Rotashield vaccine and intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/103\">",
"     103",
"    </a>",
"    ], and the measles, mumps, and rubella (MMR) vaccine and immune thrombocytopenia (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, several large epidemiologic studies have failed to detect an association between thimerosal and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/4,73-75,105,106\">",
"     4,73-75,105,106",
"    </a>",
"    ] or other developmental disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/76,77,107\">",
"     76,77,107",
"    </a>",
"    ], as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual and age-specific incidence of autism among children between 2 and 10 years of age was compared before and after discontinuation of the use of thimerosal-containing vaccines in Denmark [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/4\">",
"       4",
"      </a>",
"      ]. There was no trend toward an increase in autism during the time period when thimerosal was used (1971 to 1990). The discontinuation of the use of thimerosal-containing vaccines in 1992 was followed by an increase in the incidence of autism. Similar findings were noted in reports from Montreal [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/105\">",
"       105",
"      </a>",
"      ] and California [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a similar study, the incidence and prevalence of autism in California, Sweden, and Denmark were compared with the average exposure to thimerosal-containing vaccines [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/73\">",
"       73",
"      </a>",
"      ]. In each region, the incidence and prevalence of autism and ASD began to increase after 1985 and increased at an accelerated rate in the early 1990s. However, exposure to thimerosal-containing vaccines during this period varied by location, decreasing in Sweden and Denmark, and increasing in the United States. These results are inconsistent with the hypothesis that increased exposure to thimerosal accounts for the apparent increase in the rates of autism.",
"     </li>",
"     <li>",
"      The potential toxicity of thimerosal-containing vaccines among infants was evaluated in a two-phase retrospective cohort study using computerized health maintenance organization databases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/74\">",
"       74",
"      </a>",
"      ]. No association between thimerosal-containing vaccines and autism was detected. However, conflicting results regarding an association between thimerosal-containing vaccines and tics or language delay were found at different health maintenance organizations.",
"     </li>",
"     <li>",
"      A population-based cohort study compared the rate ratio of autism and ASD among Danish children vaccinated with thimerosal-containing and thimerosal-free preparations of the same vaccine in Denmark [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/75\">",
"       75",
"      </a>",
"      ]. The risk of autism and ASD was similar in both groups, and no dose-response association was detected.",
"     </li>",
"     <li>",
"      A prospective population-based cohort study in the United Kingdom compared measures of mercury exposure from thimerosal-containing vaccines at three, four, and six months with measures of cognitive and behavioral development from 6 to 91 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/76\">",
"       76",
"      </a>",
"      ]. No convincing associations between exposure to thimerosal and neurologic or psychologic outcome were detected.",
"     </li>",
"     <li>",
"      A case-control study of 256 children with ASD and 752 matched controls in three managed care organizations in the United States found no increased risk of ASD with exposure to thimerosal from immunoglobulin preparations or immunizations during the prenatal period (adjusted odds ratio [OR] for ASD 1.12, 95% CI 0.83-1.51), from birth to one month of age (OR 0.88, 95% CI 0.62-1.26), from birth to seven months of age (OR 0.60, 95% CI 0.36-0.99), or from birth to 20 months of age (OR 0.60, 95% CI 0.32-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/106\">",
"       106",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A survey and review of medical records of 214 families of children with ASD found that Rh-negative status was no more common among mothers of children with ASD than in the general population. In addition, exposure to thimerosal containing Rh immune globulin was not increased in children with ASD compared with children with de novo chromosome disorders, and pregnancies resulting in children with ASD were no more likely to be Rh-incompatible than those in the general population.",
"     </li>",
"     <li>",
"      The association between current neuropsychologic performance (as assessed by 42 outcomes) and exposure to thimerosal during the prenatal period and first seven months of life was evaluated in 1047 children (7 to 10 years of age) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/107\">",
"       107",
"      </a>",
"      ]. The associations that were detected were small and almost equally divided between positive and negative effects, suggesting that they were chance findings related to the large number of statistical tests performed. The overall pattern of findings did not support a causal association between thimerosal and deficits of neuropsychologic function at 7 to 10 years of age.",
"      <br/>",
"      <br/>",
"      One of the associations that were detected was between early exposure to thimerosal and tics in boys. This association has been described previously, although inconsistently [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/74,77\">",
"       74,77",
"      </a>",
"      ], and warrants further attention in future studies.",
"     </li>",
"     <li>",
"      A similar study evaluated neuropsychologic performance (as assessed by 24 outcomes) in 1403 children 10 years after participation in a vaccine study in which they received vaccines that contained 62.5 or 137.5 mcg of thimerosal [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/109\">",
"       109",
"      </a>",
"      ]. Only two outcomes were associated with increased thimerosal exposure. The associations were based on small differences in mean test scores, of doubtful clinical significance, and inconsistent with findings from other studies, suggesting that they were chance findings related to the large number of statistical tests performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER CHRONIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statistical associations between cardiovascular effects and exposure to mercury, primarily methylmercury, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/56,110-113\">",
"     56,110-113",
"    </a>",
"    ]. One study described a direct relation between mercury concentration and the risk of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/110\">",
"     110",
"    </a>",
"    ]. However, a nested case-control study among male health professionals found no such association [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/114\">",
"     114",
"    </a>",
"    ]. The reasons for these conflicting results are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROVEN BENEFITS OF VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of evidence for an association between exposure to thimerosal-containing vaccines and autism. On the other hand, the benefits of vaccines are clear. As illustrated below, several infectious diseases that were once associated with significant morbidity and mortality have been almost completely eliminated through the development, distribution, and almost universal administration of protective vaccines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wild-strain poliomyelitis has been eliminated from the Western hemisphere. No case has been reported in the United States since 1979. The last known case in the Western hemisphere was reported in Peru in 1992. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"       \"Poliovirus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The number of reported measles cases in the United States has fallen substantially since the early 1990s, when the uniform recommendation was made that all children, adolescents, and young adults without history of natural measles disease receive two doses of measles vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Between 1987 (when the",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b [Hib] conjugate vaccine was introduced in the United States) and 2000, the number of invasive Hib cases in children younger than five years of age declined by &gt;99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/115,116\">",
"       115,116",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link\">",
"       \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the declining incidence of these once-common infectious diseases, parents of young children may no longer appreciate the potential severity or dire consequences of vaccine-preventable illnesses. Parents who lack such appreciation may be willing to forego immunizations for their children, particularly if unproven risks (eg, autism and autism spectrum disease [ASD]) are highly publicized. When this occurs, immunization rates decline, and outbreaks of infectious diseases, such as measles or pertussis, may occur with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/117-120\">",
"     117-120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, between 35 and 100 of every 100,000 patients with measles disease develop acute encephalitis, which has a mortality rate of 10 percent and causes neurologic damage in 25 percent of survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/119,121-123\">",
"     119,121-123",
"    </a>",
"    ]. In addition to acute encephalitis, meningitis, subacute sclerosing panencephalitis, and acute disseminated encephalomyelitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/121,122,124\">",
"     121,122,124",
"    </a>",
"    ]. Even in uncomplicated cases of measles, as many as 50 percent of patients may have EEG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/36/21066/abstract/121,125\">",
"     121,125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"       \"Patient information: Autism spectrum disorders (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16306451\">",
"    <span class=\"h1\">",
"     OUTSIDE SOURCES OF PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccinesafety/Concerns/thimerosal/index.html\">",
"     US Centers for Disease Control and Prevention",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228\">",
"     US Food and Drug Administration",
"    </a>",
"    provide additional information about thimerosal and vaccines. They include sections on frequently asked questions that may be helpful when discussing these issues with parents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains questionable whether thimerosal contained in childhood vaccines in the past, and in the minute amounts contained in a small number of vaccines at present, increases the risk of neurologic disability or autism in children. Nonetheless, several conclusions can be drawn from the discussion in this topic review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of autism and autism spectrum disease (ASD) appears to have increased over the last several decades. Much of this trend is accounted for by changes in case definition and increased awareness of autism. Whether or not the actual incidence of autism has increased is unclear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Apparent increase in autism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple large, well-designed epidemiologic studies and systematic reviews have found insufficient evidence to support an association between thimerosal and autism or other developmental disorders. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lack of evidence for association between thimerosal and autism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similarly, a well-designed epidemiologic study failed to find an association between thimerosal and cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other chronic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of childhood vaccines has led to a decline in the incidence of childhood diseases that can have severe sequelae. Withholding vaccines from a child because of a hypothetical risk places the child at risk for actual infection that may have actual sequelae. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Proven benefits of vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the American Academy of Pediatrics and US Public Health Service recommend the use of thimerosal-free vaccines for children whenever possible, they believe that the risk of not vaccinating children because thimerosal-free vaccines are not available exceeds the risk of exposure to thimerosal-containing vaccines. The World Health Organization advisory committee concluded in a report published in 2002 that it was safe to continue using thimerosal in vaccines. The Institute of Medicine has concluded that evidence favors rejection of a causal relationship between thimerosal-containing vaccines and autism. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Though neither specific childhood vaccines nor vaccine components, such as thimerosal, have been proven by scientific study to have a causal relationship with the development of autism, there is evidence that other factors, including genetics, are important in the development of autism. These factors are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H12#H12\">",
"       \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     California Health and Human Services. Department of Developmental Services. Changes in the population of persons with autism and pervasive developmental disorders in California's developmental services system: 1987 through 1998. A Report to the Legislature, March 1, 1999. www.dds.ca.gov/autism/pdf/autism_report_1999.pdf. (Accessed on March 8, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/2\">",
"      Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/3\">",
"      Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/4\">",
"      Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 2003; 112:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/5\">",
"      Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/6\">",
"      Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003; 289:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/7\">",
"      Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/8\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/9\">",
"      McCormick MC. The autism \"epidemic\": impressions from the perspective of immunization safety review. Ambul Pediatr 2003; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/10\">",
"      Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/11\">",
"      Wakefield AJ, Montgomery SM. Autism, viral infection and measles-mumps-rubella vaccination. Isr Med Assoc J 1999; 1:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/12\">",
"      Bernard S, Enayati A, Redwood L, et al. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/13\">",
"      Bernard S, Enayati A, Roger H, et al. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7 Suppl 2:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/14\">",
"      Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopment disorders and heart disease in the United States. J Am Physicians Surg 2003; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/15\">",
"      Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003; 228:660.",
"     </a>",
"    </li>",
"    <li>",
"     Byrd RS, Segman M, Bono M. Report to the Legislature on the principal findings from the epidemiology of autism in California: a comprehensive pilot study. University of California, Davis, M.I.N.D. Institute, October 17, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/17\">",
"      Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002; 32:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/18\">",
"      Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/19\">",
"      Hoshino Y, Kumashiro H, Yashima Y, et al. The epidemiological study of autism in Fukushima-ken. Folia Psychiatr Neurol Jpn 1982; 36:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/20\">",
"      Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006; 117:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/21\">",
"      Miles JH, Takahashi TN. Lack of association between Rh status, Rh immune globulin in pregnancy and autism. Am J Med Genet A 2007; 143A:1397.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Thimerosal in vaccines. file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228 (Accessed on April 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/23\">",
"      Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis 1988; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/24\">",
"      Clements CJ, Ball LK, Ball R, Pratt RD. Thiomersal in vaccines: is removal warranted? Drug Saf 2001; 24:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/25\">",
"      Redwood L, Bernard S, Brown D. Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 2001; 22:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/26\">",
"      Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/27\">",
"      Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics 1999; 104:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/28\">",
"      Thimerosal in vaccines--An interim report to clinicians. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Pediatrics 1999; 104:570.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman JM. Myths regarding immunization. In: An Ounce of Prevention: Communicating the Benefits and Risks of Vaccines to Parents. Infectious Diseases in Children. Slack Incorporated, Thorofare, NJ 2003. p.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/30\">",
"      Strategic Advisory Group of Experts.. Vaccines and biologicals. Recommendations from the Strategic Advisory Group of Experts. Wkly Epidemiol Rec 2002; 77:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/31\">",
"      Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003; 112:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/32\">",
"      Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations. N Engl J Med 2003; 349:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatrics, Advisory Committee on Immunization Practices, Public Health Service. MMWR Morb Mortal Wkly Rep 2000; 49:622, 631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Impact of the 1999 AAP/USPHS joint statement on thimerosal in vaccines on infant hepatitis B vaccination practices. MMWR Morb Mortal Wkly Rep 2001; 50:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/36\">",
"      Oram RJ, Daum RS, Seal JB, Lauderdale DS. Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine. JAMA 2001; 285:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/37\">",
"      Schier JG, Hoffman RS. Treatment of sarin exposure. JAMA 2004; 291:182; author reply 182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/38\">",
"      Brayden RM, Pearson KA, Jones JS, et al. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. J Pediatr 2001; 138:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/39\">",
"      Biroscak BJ, Fiore AE, Fasano N, et al. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics 2003; 111:e645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/40\">",
"      Hurie MB, Saari TN, Davis JP. Impact of the Joint Statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices. Pediatrics 2001; 107:755.",
"     </a>",
"    </li>",
"    <li>",
"     Study fails to show a connection between thimerosal and autism. American Academy of Pediatrics. Posted May 16, 2003. Available at: www.cispimmunize.org/pro/doc/Geiersummary.doc. (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/42\">",
"      Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol 2001; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/43\">",
"      Stajich GV, Lopez GP, Harry SW, Sexson WR. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr 2000; 136:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/44\">",
"      Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/45\">",
"      Pichichero ME, Gentile A, Giglio N, et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 2008; 121:e208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/46\">",
"      Nielsen JB, Andersen O, Grandjean P. Evaluation of mercury in hair, blood and muscle as biomarkers for methylmercury exposure in male and female mice. Arch Toxicol 1994; 68:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/47\">",
"      Matheson DS, Clarkson TW, Gelfand EW. Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin. J Pediatr 1980; 97:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/48\">",
"      Axton JH. Six cases of poisoning after a parenteral organic mercurial compound (Merthiolate). Postgrad Med J 1972; 48:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/49\">",
"      Rohyans J, Walson PD, Wood GA, MacDonald WA. Mercury toxicity following merthiolate ear irrigations. J Pediatr 1984; 104:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/50\">",
"      Pfab R, M&uuml;ckter H, Roider G, Zilker T. Clinical course of severe poisoning with thiomersal. J Toxicol Clin Toxicol 1996; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/51\">",
"      HAY WJ, RICKARDS AG, McMENEMEY WH, CUMINGS JN. Organic mercurial encephalopathy. J Neurol Neurosurg Psychiatry 1963; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/52\">",
"      Cinca I, Dumitrescu I, Onaca P, et al. Accidental ethyl mercury poisoning with nervous system, skeletal muscle, and myocardium injury. J Neurol Neurosurg Psychiatry 1980; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/53\">",
"      Myers GJ, Davidson PW, Cox C, et al. Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study. Lancet 2003; 361:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/54\">",
"      Davidson PW, Kost J, Myers GJ, et al. Methylmercury and neurodevelopment: reanalysis of the Seychelles Child Development Study outcomes at 66 months of age. JAMA 2001; 285:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/55\">",
"      Grandjean P, Weihe P, White RF, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 1997; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/56\">",
"      S&oslash;rensen N, Murata K, Budtz-J&oslash;rgensen E, et al. Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology 1999; 10:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/57\">",
"      Murata K, Weihe P, Budtz-J&oslash;rgensen E, et al. Delayed brainstem auditory evoked potential latencies in 14-year-old children exposed to methylmercury. J Pediatr 2004; 144:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/58\">",
"      Myers GJ, Davidson PW, Cox C, et al. Twenty-seven years studying the human neurotoxicity of methylmercury exposure. Environ Res 2000; 83:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/59\">",
"      Aschner M. Mercury toxicity. J Pediatr 2001; 138:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/60\">",
"      Smith JC, Farris FF. Methyl mercury pharmacokinetics in man: a reevaluation. Toxicol Appl Pharmacol 1996; 137:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/61\">",
"      Magos L, Brown AW, Sparrow S, et al. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985; 57:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/62\">",
"      Pichichero ME, Gentile A, Giglio N, et al. Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. J Pediatr 2009; 155:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/63\">",
"      Kerper LE, Ballatori N, Clarkson TW. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 1992; 262:R761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/64\">",
"      Nelson KB, Bauman ML. Thimerosal and autism? Pediatrics 2003; 111:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/65\">",
"      SUZUKI T, MIYAMA T, KATSUNUMA H. COMPARATIVE STUDY OF BODILY DISTRIBUTION OF MERCURY IN MICE AFTER SUBCUTANEOUS ADMINISTRATION OF METHYL, ETHYL AND N-PROPYL MERCURY ACETATES. Jpn J Exp Med 1963; 33:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/66\">",
"      Amin-Zaki L, Majeed MA, Greenwood MR, et al. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. J Appl Toxicol 1981; 1:210.",
"     </a>",
"    </li>",
"    <li>",
"     Stratton K, Gable A, McCormick MC. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders, National Academy Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     Cave S. Mercury in medicine: Are we taking unnecessary risks? Hearing before the Committee on Government Reform, US House of Representatives, July 18, 2000.",
"    </li>",
"    <li>",
"     Bradstreet J. Autism - Why the increased rates? One-year update. Hearing before the Committee on Government Reform, US House of Representatives, April 25, 2001. Available at: www.gpo.gov/fdsys/pkg/CHRG-107hhrg76856/pdf/CHRG-107hhrg76856.pdf (Accessed on April 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/70\">",
"      Aschner M, Walker SJ. The neuropathogenesis of mercury toxicity. Mol Psychiatry 2002; 7 Suppl 2:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/71\">",
"      Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 2003; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization Safety Review: Vaccines and Autism. A report of the Institute of Medicine., The National Academies Press, Washington, DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/73\">",
"      Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/74\">",
"      Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003; 112:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/75\">",
"      Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/76\">",
"      Heron J, Golding J, ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics 2004; 114:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/77\">",
"      Andrews N, Miller E, Grant A, et al. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics 2004; 114:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/78\">",
"      Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004; 114:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/79\">",
"      Kark RA, Poskanzer DC, Bullock JD, Boylen G. Mercury poisoning and its treatment with N-acetyl-D,L-penicillamine. N Engl J Med 1971; 285:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/80\">",
"      Eto K. Minamata disease. Neuropathology 2000; 20 Suppl:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/81\">",
"      Korogi Y, Takahashi M, Hirai T, et al. Representation of the visual field in the striate cortex: comparison of MR findings with visual field deficits in organic mercury poisoning (Minamata disease). AJNR Am J Neuroradiol 1997; 18:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/82\">",
"      Wong V, Wong SN. Brainstem auditory evoked potential study in children with autistic disorder. J Autism Dev Disord 1991; 21:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/83\">",
"      Gomot M, Giard MH, Adrien JL, et al. Hypersensitivity to acoustic change in children with autism: electrophysiological evidence of left frontal cortex dysfunctioning. Psychophysiology 2002; 39:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/84\">",
"      O'Neill M, Jones RS. Sensory-perceptual abnormalities in autism: a case for more research? J Autism Dev Disord 1997; 27:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/85\">",
"      Torres AD, Rai AN, Hardiek ML. Mercury intoxication and arterial hypertension: report of two patients and review of the literature. Pediatrics 2000; 105:E34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/86\">",
"      Boyd AS, Seger D, Vannucci S, et al. Mercury exposure and cutaneous disease. J Am Acad Dermatol 2000; 43:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/87\">",
"      Dantzig PI. A new cutaneous sign of mercury poisoning? J Am Acad Dermatol 2003; 49:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/88\">",
"      Fuortes LJ, Weismann DN, Graeff ML, et al. Immune thrombocytopenia and elemental mercury poisoning. J Toxicol Clin Toxicol 1995; 33:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/89\">",
"      Maghazaji HI. Psychiatric aspects of methylmercury poisoning. J Neurol Neurosurg Psychiatry 1974; 37:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/90\">",
"      Ross WD, Sholiton MC. Specificity of psychiatric manifestations in relation to neurotoxic chemicals. Acta Psychiatr Scand Suppl 1983; 303:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/91\">",
"      Powell TJ. Chronic neurobehavioural effects of mercury poisoning on a group of Zulu chemical workers. Brain Inj 2000; 14:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/92\">",
"      Ramirez GB, Cruz MC, Pagulayan O, et al. The Tagum study I: analysis and clinical correlates of mercury in maternal and cord blood, breast milk, meconium, and infants' hair. Pediatrics 2000; 106:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/93\">",
"      Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA 2003; 290:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/94\">",
"      Davidovitch M, Patterson B, Gartside P. Head circumference measurements in children with autism. J Child Neurol 1996; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/95\">",
"      Lainhart JE, Piven J, Wzorek M, et al. Macrocephaly in children and adults with autism. J Am Acad Child Adolesc Psychiatry 1997; 36:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/96\">",
"      Stevenson RE, Schroer RJ, Skinner C, et al. Autism and macrocephaly. Lancet 1997; 349:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/97\">",
"      Nierenberg DW, Nordgren RE, Chang MB, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 1998; 338:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/98\">",
"      Kemper TL, Bauman ML. Neuropathology of infantile autism. Mol Psychiatry 2002; 7 Suppl 2:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/99\">",
"      Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/100\">",
"      Ritvo ER, Freeman BJ, Scheibel AB, et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 1986; 143:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/101\">",
"      Bailey A, Luthert P, Dean A, et al. A clinicopathological study of autism. Brain 1998; 121 ( Pt 5):889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/102\">",
"      Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/103\">",
"      Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/104\">",
"      Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/105\">",
"      Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118:e139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/106\">",
"      Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics 2010; 126:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/107\">",
"      Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007; 357:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/108\">",
"      Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry 2008; 65:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/109\">",
"      Tozzi AE, Bisiacchi P, Tarantino V, et al. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines. Pediatrics 2009; 123:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/110\">",
"      Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002; 347:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/111\">",
"      Salonen JT, Sepp&auml;nen K, Lakka TA, et al. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000; 148:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/112\">",
"      Salonen JT, Sepp&auml;nen K, Nyyss&ouml;nen K, et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995; 91:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/113\">",
"      Grandjean P, Murata K, Budtz-J&oslash;rgensen E, Weihe P. Cardiac autonomic activity in methylmercury neurotoxicity: 14-year follow-up of a Faroese birth cohort. J Pediatr 2004; 144:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/114\">",
"      Yoshizawa K, Rimm EB, Morris JS, et al. Mercury and the risk of coronary heart disease in men. N Engl J Med 2002; 347:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/115\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/116\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/117\">",
"      The measles epidemic. The problems, barriers, and recommendations. The National Vaccine Advisory Committee. JAMA 1991; 266:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/118\">",
"      Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/119\">",
"      White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/120\">",
"      Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/121\">",
"      M&auml;kel&auml; A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/122\">",
"      Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med 1984; 310:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/123\">",
"      Weibel RE, Caserta V, Benor DE, Evans G. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998; 101:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/36/21066/abstract/124\">",
"      Roos RP, Graves MC, Wollmann RL, et al. Immunologic and virologic studies of measles inclusion body encephalitis in an immunosuppressed host: the relationship to subacute sclerosing panencephalitis. Neurology 1981; 31:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Brooks GF, Butel JS, Morse SA. Paramyxoviruses and rubella virus. In: Jawetz, Melnick, &amp; Adelberg's Medical Microbiology, 21st, Butler JP, Ransom J, Ryan E (Eds), Appleton &amp; Lange, Stamford, CT 1998. p.50.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2843 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21066=[""].join("\n");
var outline_f20_36_21066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPARENT INCREASE IN AUTISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impact of controversy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mercury toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Methylmercury versus ethylmercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSSIBLE ASSOCIATION BETWEEN THIMEROSAL AND AUTISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LACK OF EVIDENCE FOR ASSOCIATION BETWEEN THIMEROSAL AND AUTISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86482543\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comparison of clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Biologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epidemiologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER CHRONIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROVEN BENEFITS OF VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16306451\">",
"      OUTSIDE SOURCES OF PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/59/32699\" title=\"table 1\">",
"      Mercury poisoning versus autism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_36_21067="Autoimmune diseases in RPC";
var content_f20_36_21067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of coexisting autoimmune diseases in 645 patients with relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitis",
"       </td>",
"       <td>",
"        73*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid disease",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus erythematous",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren's syndrome",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behcet's disease",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ankylosing spondylitis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriatic arthritis",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic sclerosis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyalgia rheumatica",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal fibrosis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Encompasses both primary and secondary forms of vasculitis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21067=[""].join("\n");
var outline_f20_36_21067=null;
var title_f20_36_21068="Symptoms and signs of anaphylaxis";
var content_f20_36_21068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feeling of warmth, flushing (erythema), itching (may occur in areas, such as external auditory canals, palms, soles, or groin), urticaria, angioedema, morbilliform rash, and \"hair standing on end\" (pilor erection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Oral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Itching or tingling of lips, tongue, or palate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Edema of lips, tongue, uvula, metallic taste",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nose - itching, congestion, rhinorrhea, and sneezing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Laryngeal - itching and \"tightness\" in the throat, dysphonia, hoarseness, stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower airways - shortness of breath (dyspnea), chest tightness, deep or repetitive cough, wheezing, and cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nausea, abdominal pain (colic, cramps), vomiting (large amounts of \"stringy\" mucus), diarrhea, and dysphagia (difficulty swallowing*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feeling of faintness or dizziness; syncope, altered mental status, chest pain, palpitations, tachycardia, bradycardia or other dysrhythmia, hypotension, tunnel vision, difficulty hearing, urinary or fecal incontinence, and cardiac arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anxiety, apprehension, sense of impending doom, seizures, headache",
"        <sup>",
"         &bull;",
"        </sup>",
"        , and confusion; children may become irritable, cease to play, or have other sudden behavioral changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ocular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Periorbital itching, erythema and edema, tearing, and conjunctival erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uterine cramps and bleeding in women and girls",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Often occurs in association with throat tightness and other upper airway symptoms.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Not common in anaphylaxis overall; however, reported in up to 30 percent of patients with exercise-induced anaphylaxis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21068=[""].join("\n");
var outline_f20_36_21068=null;
var title_f20_36_21069="WHO class salivary gld tum";
var content_f20_36_21069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO histological classification of tumours of the salivary glands",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignant epithelial tumours",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acinic cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucoepidermoid carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenoid cystic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polymorphous low-grade adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epithelial-myoepithelial carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clear cell carcinoma, not otherwise specified",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Basal cell adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sebaceous carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sebaceous lymphadenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystadenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Low-grade cribriform cystadenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucinous adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oncocytic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salivary duct carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenocarcinoma, not otherwise specified",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myoepithelial carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carcinoma ex pleomorphic adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carcinosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastasizing pleomorphic adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Large cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoepithelial carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sialoblastoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Benign epithelial tumours",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pleomorphic adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myoepithelioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Basal cell adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Warthin tumour",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oncocytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Canalicular adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sebaceous adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Lymphadenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sebaceous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Non-sebaceous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Ductal papillomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inverted ductal papilloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Intraductal papilloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sialadenoma papilliferum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystadenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Soft tissue tumours",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haemangioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Haematolymphoid tumours",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hodgkin lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diffuse large B-cell lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Extranodal marginal zone B-cell lymphoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours, IARC Press, Lyon 2005. Copyright &copy; 2005 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21069=[""].join("\n");
var outline_f20_36_21069=null;
var title_f20_36_21070="VT VF non ST elevation ACS";
var content_f20_36_21070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    VT and VF predict mortality in non-ST elevation ACS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 391px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of a pooled analysis of four major trials of over 25,000 patients with a non-ST elevation acute coronary syndrome (ACS, including non-ST elevation infarction and unstable angina). The overall incidence of ventricular tachycardia (VT) or ventricular fibrillation (VF) was 2.1 percent. VT and VF were significant predictors of increased mortality at both 30 days and six months (adjusted hazard ratio 8 and 5, respectively, for VT, and 23 and 15 for VF); the risk was increased further in patients with both VT and VF. The increase in risk was largely due to more deaths in the first 30 days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Al-Khatib SM, Granger CB, Huang Y, et al. Circulation 2002; 106:309.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_36_21070=[""].join("\n");
var outline_f20_36_21070=null;
var title_f20_36_21071="Contents: Disorders of bone";
var content_f20_36_21071=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Disorders of bone",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Disorders of bone",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/26/11687\">",
"           Bone disease in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17593\">",
"           Bone disease with hyperthyroidism and thyroid hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43829\">",
"           Endocrine dysfunction in the nephrotic syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hereditary disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21209\">",
"           Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38040\">",
"           Osteogenesis imperfecta: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26185\">",
"           Osteogenesis imperfecta: Management and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperparathyroidism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3287\">",
"           Hungry bone syndrome following parathyroidectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8954\">",
"           Management of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13688\">",
"           Parathyroid carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40387\">",
"           Parathyroid cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21416\">",
"           Parathyroid hormone assays and their clinical use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36744\">",
"           Parathyroid hormone secretion and action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple endocrine neoplasia syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38871\">",
"           Multiple endocrine neoplasia type 1: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteomalacia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11416\">",
"           Clinical manifestations, diagnosis, and treatment of osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27494\">",
"           Epidemiology and etiology of osteomalacia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36213\">",
"           Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22040\">",
"           Denosumab for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6553\">",
"           Epidemiology and etiology of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37545\">",
"           Evaluation and management of aromatase inhibitor-induced bone loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42553\">",
"           Evaluation and treatment of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37178\">",
"           Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29354\">",
"           Osteoporotic fracture risk assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42583\">",
"           Overview of dual-energy x-ray absorptiometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/26/15786\">",
"           Parathyroid hormone therapy for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11333\">",
"           Pharmacology of bisphosphonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/21/33113\">",
"           Prevention of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41481\">",
"           Selective estrogen receptor modulators for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36969\">",
"           Antiepileptic drugs and bone disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42519\">",
"           Bone physiology and biochemical markers of bone turnover",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9562\">",
"           Drugs that affect bone metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30569\">",
"           Metabolic bone disease in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29830\">",
"           Metabolic bone disease in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34906\">",
"           Normal skeletal development and regulation of bone formation and resorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28346\">",
"           Osteonecrosis (avascular necrosis of bone)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paget disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/50/7978\">",
"           Clinical manifestations and diagnosis of Paget disease of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10602\">",
"           Treatment of Paget disease of bone",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal osteodystrophy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28343\">",
"           Bone biopsy and the diagnosis of renal osteodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vitamin D",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38184\">",
"           Causes of vitamin D deficiency and resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31193\">",
"           Vitamin D and extraskeletal health",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E4D6023FD2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_36_21071=[""].join("\n");
var outline_f20_36_21071=null;
